[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4754
1. Gelain ME, Rossi G, Giori L, Comazzi S, Paltrinieri S: Identification of neoplastic cells in blood using the Sysmex XT-2000iV: a preliminary step in the diagnosis of canine leukemia. Vet Clin Pathol; 2010 Jun;39(2):169-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of neoplastic cells in blood using the Sysmex XT-2000iV: a preliminary step in the diagnosis of canine leukemia.
  • BACKGROUND: Classification of leukemias requires specialized diagnostic techniques.
  • METHODS: Blood samples (n=160) were grouped into 5 categories: acute leukemia (n=30), chronic leukemia (n=15), neoplasia without blood involvement (n=41), non-neoplastic reactive conditions (n=31), and healthy dogs (n=43).
  • The more objective approach based on the generation of a "leukemic flag" had a sensitivity of 100%, specificity of 87.0%, LR- of 0.00, and LR+ of 7.67.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230575.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Abdulkarim K, Girodon F, Johansson P, Maynadié M, Kutti J, Carli PM, Bovet E, Andréasson B: AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol; 2009 Feb;82(2):106-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (MPD) have an inherent tendency for transformation into acute myelogenous leukaemia (AML).
  • Over a median observation time of 15 yr, 56 subjects (7%) out of a total of 795 patients with Ph- MPD transformed to AML.
  • In IMF, the average time from diagnosis to AML transformation was 42 +/- 33 months, which was significantly shorter than for both PV and ET (88 +/- 56 and 76 +/- 57 months; P = 0.0075 and P = 0.027, respectively).
  • The time from diagnosis to AML transformation appears to be a continuous event as regards all three MPD entities.
  • [MeSH-major] Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / pathology. Myeloproliferative Disorders / pathology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19134023.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


3. Wan TS, So CC, Hui KC, Yip SF, Ma ES, Chan LC: Diagnostic utility of dual fusion PML/RARalpha translocation DNA probe (D-FISH) in acute promyelocytic leukemia. Oncol Rep; 2007 Apr;17(4):799-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of dual fusion PML/RARalpha translocation DNA probe (D-FISH) in acute promyelocytic leukemia.
  • Translocation(15;17) leading to the formation of fusion gene PML/RARalpha is the diagnostic hallmark of acute promyelocytic leukemia (APL).
  • Using a dual color dual fusion (D-FISH) PML/RARalpha translocation DNA probe which hybridises both to PML/RARalpha and RARalpha/PML fusion genes, we characterised the FISH pattern of 52 APL patients at diagnosis and correlated the findings with conventional cytogenetics and RT-PCR analysis.
  • In summary, PML/RARalpha D-FISH is a highly sensitive method for confirming diagnosis of APL.
  • However D-FISH cannot be solely relied on for the diagnosis of APL owing to atypical patterns which are infrequently observed in cases with additional 17q structural abnormalities, gene insertion and gene duplication.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Leukemia, Promyelocytic, Acute / diagnosis. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342318.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Probes; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  •  go-up   go-down


Advertisement
4. Platten M, Opitz CA, Kohlhof P, Hegenbart U, Ho AD, Wick W: Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia. Neurology; 2007 Aug 14;69(7):707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemic Infiltration / diagnosis. Pain / etiology. Peripheral Nervous System Diseases / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Sural Nerve / pathology


5. Shaw BE, Russell NH: Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant; 2008 Mar;41(5):495-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.
  • The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952130.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  • [Number-of-references] 91
  •  go-up   go-down


6. Papantoniou N, Daskalakis G, Marinopoulos S, Anastasakis E, Mesogitis S, Antsaklis A: Management of pregnancy in adolescence complicated by acute lymphoblastic leukemia. Fetal Diagn Ther; 2008;23(2):164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of pregnancy in adolescence complicated by acute lymphoblastic leukemia.
  • The management of the common acute lymphoblastic leukemia in pregnancy has been controversial.
  • We report a case of a 16-year-old primigravida with acute lymphoblastic leukemia, first presented in pregnancy, which was treated with aggressive chemotherapy protocols.
  • Full remission of the disease was achieved.
  • The woman remains in complete remission, continuing maintenance chemotherapy, 18 months following diagnosis.
  • The offspring did not show any abnormality in physical examinations or laboratory tests and keeps growing normally 18 months after birth.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adolescent. Age Factors. Disease Management. Female. Humans. Infant, Newborn. Male. Pregnancy


7. Tokuhira M, Hanzawa K, Watanabe R, Sekiguchi Y, Nemoto T, Toyozumi Y, Tamaru J, Itoyama S, Suzuki K, Kameda H, Mori S, Kizaki M: Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report. J Hematol Oncol; 2009;2:27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.
  • Rheumatoid arthritis (RA) is an autoimmune disease mediated by inflammatory processes mainly at the joints.
  • Recently, awareness of Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder (T-LPD) has been heightened for its association with methotraxate usage in RA patients.
  • In the contrary, acute myeloid leukemia with multilineage dysplasia (AML-MLD) has never been documented to be present concomitantly with the above two conditions.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Epstein-Barr Virus Infections / complications. Leukemia, Myeloid, Acute / complications. Lymphoproliferative Disorders / complications
  • [MeSH-minor] Cell Lineage. Diagnosis. Humans. Male. Middle Aged. T-Lymphocytes / pathology


8. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, Jaffe ES: Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica; 2010 Nov;95(11):1873-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications.
  • BACKGROUND: Blastic plasmacytoid dendritic cell neoplasm is a rare malignancy that typically follows a highly aggressive clinical course in adults, whereas experience in children with this disease is very limited.
  • DESIGN AND METHODS: This retrospective study analyzed the pathological and clinical findings of nine cases of blastic plasmacytoid dendritic cell neoplasm presenting in patients under the age of 18 years who were reviewed at our institution.
  • Nine patients were alive 5 years after the original diagnosis, although only three of them had undergone hematopoietic stem cell transplantation--one in first complete remission and two in second remission.
  • Of the seven patients who lacked cutaneous disease at presentation, 100% survived, including five who were alive more than 5 years after diagnosis, although only two had undergone stem cell transplantation.
  • Among the 18 patients who presented with cutaneous disease and for whom follow-up data were available, only 11 survived (61%).
  • Unexpectedly, three of four cases of blastic plasmacytoid dendritic cell neoplasm tested showed focal positivity for S-100.
  • S-100 was negative in 28 cases of acute myeloid leukemia evaluated for this marker.
  • CONCLUSIONS: In contrast to adult cases, in which long-term survival depends on stem cell transplantation in first complete remission, blastic plasmacytoid dendritic cell neoplasms in children are clinically less aggressive.
  • Treatment with high-risk acute lymphoblastic leukemia-type chemotherapy appears to be effective, and stem cell transplantation may be reserved for children who relapse and achieve a second remission.
  • Outcomes were more favorable in cases that lacked cutaneous disease at presentation, although a comparison of cutaneous and non-cutaneous cases might be confounded by differences in treatment regimens.
  • Focal expression of S-100 may be seen in concert with other markers of plasmacytoid dendritic cells.

  • Genetic Alliance. consumer health - Blastic Plasmacytoid Dendritic Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6037-46 [11086035.001]
  • [Cites] Br J Dermatol. 2010 Jan;162(1):74-9 [19689477.001]
  • [Cites] Blood. 2001 May 15;97(10):3210-7 [11342451.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1556-63 [11861268.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):852-62 [12131152.001]
  • [Cites] Leuk Res. 2002 Sep;26(9):803-7 [12127554.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5007-9 [12576313.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):294-8 [12950240.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):637-46 [13130309.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1366-74 [14508398.001]
  • [Cites] Eur J Immunol. 2004 Feb;34(2):418-26 [14768046.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1097-108 [15205205.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):307-13 [15323148.001]
  • [Cites] Diagn Mol Pathol. 1992 Sep;1(3):173-9 [1342963.001]
  • [Cites] Ann Intern Med. 1999 Oct 5;131(7):549-50 [10507983.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1219-26 [15549123.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1256-64 [15388576.001]
  • [Cites] J Korean Med Sci. 2005 Apr;20(2):319-24 [15832009.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):662-75 [15981806.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1274-83 [16160468.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):715-25 [16690531.001]
  • [Cites] Haematologica. 2006 Dec;91(12 Suppl):ECR48 [17194654.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1720-7 [17068154.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):687-700 [17439829.001]
  • [Cites] Am J Clin Pathol. 2007 Sep;128(3):445-53 [17709319.001]
  • [Cites] Haematologica. 2007 Sep;92(9):e91-3 [17768139.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Nov;29(11):766-9 [17984695.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3778-92 [18218851.001]
  • [Cites] Immunity. 2008 Sep 19;29(3):352-61 [18799143.001]
  • [Cites] Blood. 2009 Apr 9;113(15):3418-27 [19176316.001]
  • [Cites] Science. 2009 Apr 17;324(5925):392-7 [19286519.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 May;31(5):339-43 [19415013.001]
  • [Cites] Br J Haematol. 2009 Jun;145(5):624-36 [19388928.001]
  • [Cites] Cytometry B Clin Cytom. 2009 Jul;76(4):237-48 [19382197.001]
  • [Cites] Adv Anat Pathol. 2009 Nov;16(6):392-404 [19851130.001]
  • [Cites] Am J Surg Pathol. 2010 Jan;34(1):75-87 [19956058.001]
  • [Cites] Leuk Res. 2010 Apr;34(4):438-46 [19793612.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):405-17 [20154586.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):642-6 [11241229.001]
  • (PMID = 20663945.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  • [Other-IDs] NLM/ PMC2966909
  •  go-up   go-down


9. Essa EA, El Halim SM, Abo-Elenin A, El Bendary A, Abdou SH, Farag W: Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia. Egypt J Immunol; 2007;14(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia.
  • In this work, reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the gene expression (mRNA) of CD30 variant (CD30v) and CD30 Ligand (CD30L) on the peripheral blood mononuclear cells (PBMCs) of 15 healthy individuals as a control group, 15 patients with newly diagnosed acute myeloid leukemia (AML) and 15 patients with newly diagnosed acute lymphocytic leukemia (ALL).
  • Patients with positive expression of CD30v and CD30L were found to have significantly increased blast cell % (p<0.001), increased total leucocytic count (P<0.001) and decreased platelets count (P<0.001) than those with negative expression.
  • As regard to immunophenotypes of ALL, positive expression was found to be significantly higher in B-cell than T-cell subtype (77.8% versus 16.7%, P=0.02).
  • Positive expression was also significantly associated with more aggressive disease and with B-cell than T-cell subtypes.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689277.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / CD30 Ligand; 0 / RNA, Messenger
  •  go-up   go-down


10. Blandin AT, Mühlematter D, Bougeon S, Gogniat C, Porter S, Beyer V, Parlier V, Beckmann JS, van Melle G, Jotterand M: Automated four-color interphase fluorescence in situ hybridization approach for the simultaneous detection of specific aneuploidies of diagnostic and prognostic significance in high hyperdiploid acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2008 Oct 15;186(2):69-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated four-color interphase fluorescence in situ hybridization approach for the simultaneous detection of specific aneuploidies of diagnostic and prognostic significance in high hyperdiploid acute lymphoblastic leukemia.
  • In high hyperdiploid acute lymphoblastic leukemia (ALL), the concurrence of specific trisomies confers a more favorable outcome than hyperdiploidy alone.
  • The large number of nuclei scored revealed a high level of chromosome variability both at diagnosis and relapse, the prognostic significance of which is of considerable clinical interest and merits further evaluation.
  • [MeSH-major] Aneuploidy. In Situ Hybridization, Fluorescence / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940469.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman LB, Chin L, Hunger SP, Sallan SE, Look AT: Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol; 2010 Aug 20;28(24):3816-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.
  • PURPOSE: To identify children with T-cell acute lymphoblastic leukemia (T-ALL) at high risk of induction chemotherapy failure by using DNA copy number analysis of leukemic cells collected at diagnosis.
  • Using a rapid and inexpensive quantitative DNA-PCR assay, we validated ABD as a predictor of a poor response to induction chemotherapy in an independent series of patients.
  • CONCLUSION: Lymphoblasts from children with T-ALL should be evaluated at diagnosis for deletion within the TCRgamma locus.
  • Patients lacking biallelic deletion, which confers a high probability of induction failure with contemporary therapy, should be assigned to alternative therapy in the context of a prospective clinical trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Comparative Genomic Hybridization. Gene Deletion. Genes, T-Cell Receptor gamma. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Alleles. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Predictive Value of Tests. Prognosis. Remission Induction. Risk Assessment. Risk Factors. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Nov;13(11):1696-707 [10557041.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Stem Cells. 2001;19(3):165-79 [11359942.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84 [14734480.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12522-7 [9770518.001]
  • [Cites] Blood. 1999 May 1;93(9):3033-43 [10216100.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1715-23 [15928199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):421-38 [17579063.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1429-38 [17495134.001]
  • [Cites] Curr Biol. 2008 Jan 8;18(1):30-6 [18158243.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1496-503 [18349402.001]
  • [Cites] Haematologica. 2008 Nov;93(11):1658-65 [18835836.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D1006-12 [18978023.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4386-93 [12036866.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2142-50 [18818707.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Curr Opin Pediatr. 2009 Feb;21(1):1-8 [19242236.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1038-45 [19494353.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] Blood. 2009 Dec 10;114(25):5136-45 [19828704.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):648-54 [19841326.001]
  • [Cites] Leukemia. 2010 Feb;24(2):371-82 [20010620.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1351-3 [20007809.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • (PMID = 20644084.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K08CA133103; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / NCI 5P01CA68484; United States / NCI NIH HHS / CA / R01 CA129382-01A1; United States / NCI NIH HHS / CA / R01 CA129382; United States / NCI NIH HHS / CA / K08 CA133103-04; United States / NCI NIH HHS / CA / K08 CA133103-01; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / L40 CA124083-01; United States / NCI NIH HHS / CA / K08 CA133103; United States / NCI NIH HHS / CA / L40 CA124083; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / K08 CA133103-03; United States / NCI NIH HHS / CA / R01CA129382; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / R01 CA120196-01A1; United States / NCI NIH HHS / CA / L40 CA124083-02; United States / NCI NIH HHS / CA / CA98413; United States / NCI NIH HHS / CA / K08 CA133103-02; United States / NCI NIH HHS / CA / P01 CA068484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940399
  •  go-up   go-down


12. Karimi M, Eshghi P: Unusual lymphoblastic leukemia/lymphoma in Eastern Iran. Indian J Pediatr; 2006 Jul;73(7):619-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual lymphoblastic leukemia/lymphoma in Eastern Iran.
  • Lymphoblastic lymphoma-leukemia (LBLL) most commonly presents with mediastinal masses (50-75%), while pleural and pericardial effusion may also be present.
  • Lymphadenopathy usually in the neck, axilla or supraclavicular regions, is considered as another typical presentation of the disease.
  • This is a case report of a six-year-old boy with unusual huge enlargement of maxilla, mandible and soft palate as well as gingival hypertrophy which led to secondary respiratory and feeding difficulties.
  • Morphologic and flowcytometric evaluation of bone marrow aspiration showed that it was a T cell type acute leukemia which may be due to dissemination of a lymphoblastic lymphoma and considered as a case of lymphoma-leukemia.
  • [MeSH-major] Gingival Hypertrophy / etiology. Jaw Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Child. Humans. Iran. Leukemia, Lymphoid / complications. Leukemia, Lymphoid / diagnosis. Male

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Blood. 1986 Feb;67(2):474-8 [3080041.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1984 Jul;64(1):38-47 [6375764.001]
  • [Cites] Cancer. 1976 Aug;38(2):964-83 [1067894.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):415-7 [356693.001]
  • [Cites] Mod Pathol. 1988 Jan;1(1):15-22 [3266334.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Oct;82(4):434-6 [8899783.001]
  • [Cites] Cancer Res. 1983 Sep;43(9):4486-90 [6191861.001]
  • [Cites] J Am Acad Dermatol. 1991 Dec;25(6 Pt 1):1023-31 [1810981.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1993 Jul;29B(3):225-9 [8298427.001]
  • [Cites] Br J Haematol. 1996 Mar;92(3):665-72 [8616033.001]
  • (PMID = 16877858.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


13. Blatt J, Greenwood R, Weig S, Rao K, Fedoriw GD, Dent G: Isolated central nervous system relapse in an adolescent with acute myelomonocytic leukemia, Charcot Marie Tooth syndrome, and paraneoplastic autoantibody. J Pediatr Hematol Oncol; 2010 Oct;32(7):571-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system relapse in an adolescent with acute myelomonocytic leukemia, Charcot Marie Tooth syndrome, and paraneoplastic autoantibody.
  • A 17-year-old boy, with acute myelomonocytic leukemia and inversion 16(p13q22) developed polyneuropathy and isolated central nervous system relapse.
  • Scoliosis and high-arched feet suggested a diagnosis of Charcot Marie Tooth (CMT) syndrome and genetic testing confirmed duplication at the PMP22 locus at chromosome 17p11.12.
  • [MeSH-major] Autoantibodies / blood. Charcot-Marie-Tooth Disease / immunology. Leukemia, Myelomonocytic, Acute / immunology. Paraneoplastic Syndromes, Nervous System / immunology

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Charcot-Marie-Tooth Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20724950.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Myelin Proteins; 0 / PMP22 protein, human
  •  go-up   go-down


14. Gupta N, Bhaskar H, Duggal S, Ghalaut PS, Kundra S, Arora DR: Primary amoebic meningoencephalitis: first reported case from Rohtak, North India. Braz J Infect Dis; 2009 Jun;13(3):236-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A fatal case of primary amoebic encephalitis (PAM) in a 20 year old boy, a proven case of acute leukemic leukemia (ALL) type L2, in remission is described.
  • The clinical presentation, the isolation of the amoeba from the cerebrospinal fluid (CSF), the poor response to amphotericin B, and the ultimately fatal outcome are all consistent with the diagnosis of PAM.
  • On the basis of its ability to grow at temperature 42 degrees C and 45 degrees C, morphology of trophozoite, and the presence of flagellate forms in CSF, the amoeba was identified as Naegleria fowleri.
  • A possibility of PAM should always be considered in all cases of acute purulent meningoencephalitis in which no bacteria or fungus are found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191204.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


15. Zivanovic S, Saranac L, Kostic G, Bogicevic V, Jovancic D: A case of acute tuberculous pleuropneumonia in a patient with acute lymphoblastic leukemia. ScientificWorldJournal; 2010;10:578-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of acute tuberculous pleuropneumonia in a patient with acute lymphoblastic leukemia.
  • We here report a 14-year-old male who was admitted to the hospital because of acute pneumonia, who had been diagnosed with acute lymphoblastic leukemia (ALL) when he was 12 years old.
  • A diagnosis of acute tuberculous pleuropneumonia was made based on clinical and radiographical findings, and Mycobacterium tuberculosis was identified by Ziehl-Neelson acid-fast stain and culture on Löwenstein-Jensen medium.
  • [MeSH-major] Pneumonia, Bacterial / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tuberculosis, Pleural / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364243.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


16. Liu J, Wu DS, Zhang S, Yan CH, Zhou Y, Zhang YD, Qi ZH: [Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia]. Beijing Da Xue Xue Bao; 2005 Jun 18;37(3):249-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the relation of the serum level of sIL-2R in relapse patients with acute lymphoblastic leukemia (ALL).
  • CONCLUSION: Monitor of the level of sIL-2R can predict impending relapse of patients with ALL and is helpful to early diagnosis of relapse.
  • [MeSH-major] Neoplasm Recurrence, Local / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, Interleukin-2 / blood

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968312.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-2
  •  go-up   go-down


17. Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S: Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. Bone Marrow Transplant; 2005 Oct;36(7):565-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.
  • Reduced-intensity stem cell transplantation (RIST) has been shown to be a safe and useful alternative transplant method for patients including elderly and medically unfit patients.
  • RIST conditioning regimens vary widely in the intensity of myeloablation, immunoablation, and antileukemia effects, and thus optimal regimen for each disease entity is yet to be determined.
  • In acute myeloid leukemia (AML), moderate-intensity regimens may be effective, achieving 30-70% 1-year disease-free survival in various series, but minimal-intensity regimens are associated with high relapse rates.
  • In acute lymphoblastic leukemia (ALL), not even moderate-intensity regimens are effective and most patients with advanced ALL relapse post transplant.
  • Thus, the risk/benefit ratios of graft-versus-host disease/graft-versus-leukemia effect differ among diseases.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Disease-Free Survival. Graft vs Host Disease. Humans. Middle Aged. Multicenter Studies as Topic. Recurrence. Time Factors. Transplantation Chimera. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995714.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 98
  •  go-up   go-down


18. Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Reichard KK, Winter SS: Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr; 2006 May;148(5):687-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
  • Transient myeloproliferative disorder (TMD) occurs in 10% of infants with Down syndrome (DS).
  • Down syndrome infants with resolved TMD may later develop acute megakaryocytic leukemia (AMKL).
  • We report on a non-DS child identified with trisomy 21 mosaicism and a GATA1 mutation in the original blast cells who has been followed for 2 years without exhibiting AMKL.
  • Currently, the risk for such infants developing acute leukemia is uncertain.
  • [MeSH-major] GATA1 Transcription Factor / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Myeloproliferative Disorders / genetics

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr. 2007 Mar;150(3):e34 [17307526.001]
  • (PMID = 16737888.001).
  • [ISSN] 0022-3476
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor
  •  go-up   go-down


19. Kars MC, Duijnstee MS, Pool A, van Delden JJ, Grypdonck MH: Being there: parenting the child with acute lymphoblastic leukaemia. J Clin Nurs; 2008 Jun;17(12):1553-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Being there: parenting the child with acute lymphoblastic leukaemia.
  • AIMS AND OBJECTIVES: To gain insight into the lived experience of parenting a child with leukaemia during treatment.
  • BACKGROUND: Diagnosis of leukaemia in children leads to an existential shock for parents and a reversal of normal family life.
  • Today, in the Netherlands, after diagnosis, children stay at home most of the time.
  • RELEVANCE TO CLINICAL PRACTICE: The concept offers an essential insight into parenting the child with acute lymphoblastic leukaemia and has relevance for nursing practice and education.
  • [MeSH-major] Attitude to Health. Parent-Child Relations. Parenting / psychology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • MedlinePlus Health Information. consumer health - Parenting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482117.001).
  • [ISSN] 1365-2702
  • [Journal-full-title] Journal of clinical nursing
  • [ISO-abbreviation] J Clin Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. El-Sissy AH, El-Mashari MA, Bassuni WY, El-Swaayed AF: Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia. J Egypt Natl Canc Inst; 2006 Sep;18(3):244-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia.
  • BACKGROUND: Immunophenotyping improves both accuracy and reproducibility of acute leukemia classification and is considered particularly useful for identifying aberrant lineage association of acute leukemia, biphenotypic and bilineal acute leukemia, as well as monitoring minimal residual disease.
  • THE AIM OF OUR STUDY: Is to determine aberrant lymphoid antigen expression in Saudi acute myeloid leukemia (AML), correlate them with FAB subtypes, evaluate early surface markers CD7 and CD56, and to investigate the role of cytoplasmic CD79a (a B cell marker that is assigned a high score of 2.0 in the WHO classification).
  • CD79a was expressed in one case together with CD19, diagnosed as acute biphenotypic leukemia, and was associated with t(8;21) (q22;q22).
  • CONCLUSION: Minimal residual disease in AML is very difficult to trace, detection of aberrant expression of lymphoid antigens will make it easier.
  • [MeSH-major] Antigens, CD56 / analysis. Antigens, CD7 / analysis. Antigens, CD79 / analysis. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Leukemia, Myeloid, Acute / diagnosis


21. Worth LJ, Seymour JF, Slavin MA: Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices. Support Care Cancer; 2009 Jul;17(7):811-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An underlying diagnosis of acute myeloid leukemia was negatively associated with CR-BSI (odds ratio (OR) 0.14, p = 0.046), and a previous diagnosis of fungal infection was associated with infection (OR 22.82, p = 0.031).

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2003 May;31(9):795-801 [12732887.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):926-31 [15824981.001]
  • [Cites] Intern Med J. 2007 Apr;37(4):284-5; author reply 258-6 [17388879.001]
  • [Cites] CCQ. 1980 Dec;3:79-88 [10249317.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):211-4 [10918433.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1215-26 [17326048.001]
  • [Cites] Support Care Cancer. 2003 Dec;11(12):790-4 [14505156.001]
  • [Cites] Infect Control Hosp Epidemiol. 2007 May;28(5):610-3 [17464926.001]
  • [Cites] Mayo Clin Proc. 2006 Sep;81(9):1159-71 [16970212.001]
  • [Cites] Clin Infect Dis. 2001 May 1;32(9):1249-72 [11303260.001]
  • [Cites] Infect Control Hosp Epidemiol. 2003 Dec;24(12):905-11 [14700405.001]
  • [Cites] J Vasc Interv Radiol. 2000 Jul-Aug;11(7):837-40 [10928518.001]
  • [Cites] Am J Infect Control. 1997 Apr;25(2):112-6 [9113287.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):433-42 [17962211.001]
  • [Cites] Arch Intern Med. 1993 Aug 9;153(15):1791-6 [8392831.001]
  • [Cites] J Vasc Interv Radiol. 2000 Nov-Dec;11(10):1309-14 [11099241.001]
  • [Cites] Support Care Cancer. 2006 Nov;14(11):1141-6 [16622649.001]
  • [Cites] J Infus Nurs. 2004 Nov-Dec;27(6):431-6 [15586107.001]
  • [Cites] J Intraven Nurs. 1993 Mar-Apr;16(2):104-9 [8478778.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Dec;23(12):759-69 [12517020.001]
  • [Cites] Am J Med. 1981 Feb;70(2):398-404 [7008588.001]
  • [Cites] Chest. 2005 Aug;128(2):489-95 [16100130.001]
  • [Cites] Eur J Cancer. 2001 Dec;37(18):2379-84 [11720831.001]
  • (PMID = 19096883.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Sedlacek P, Vavra V, Masova I, Codl D, Laznickova T, Malaskova L, Nyc O, Stary J: Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia. Mycoses; 2009 May;52(3):276-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia.
  • Diagnosis of non-Aspergillus mould infections remains challenging despite application of a wide spectrum of non-culture-based microbiological techniques.
  • In this article, we present the case of a 15-month-old boy diagnosed with Rhizopus microsporus var. rhizopodiformis liver mycetoma during induction chemotherapy for acute promyelocytic leukaemia.
  • [MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Leukemia, Myeloid, Acute / complications. Liver Diseases / therapy. Mycetoma / therapy. Rhizopus / isolation & purification. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18643916.001).
  • [ISSN] 1439-0507
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Triazoles; 0 / liposomal amphotericin B; 6TK1G07BHZ / posaconazole; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


23. Sarvis JA, Auge BK: Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia. Urology; 2009 May;73(5):1163.e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid (granulocytic) sarcoma of epididymis as rare manifestation of recurrent acute myelogenous leukemia.
  • Myeloid sarcoma involving the genitourinary system is a rare complication associated with acute myelogenous leukemia or other myeloproliferative disorders.
  • The diagnosis is made by pathologic findings of diffuse infiltration of intermediate-size neoplastic cells and fibrosis of the affected organ.
  • We report the second known case of myeloid sarcoma involving the epididymis in a patient with a history of acute myelogenous leukemia.
  • [MeSH-major] Epididymis / pathology. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow Transplantation / methods. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Recurrence. Risk Assessment. Transplantation, Homologous. Treatment Outcome. Ultrasonography, Doppler


24. Ganzitti L, Fachechi G, Driul L, Marchesoni D: Acute promyelocytic leukemia during pregnancy. Fertil Steril; 2010 Nov;94(6):2330.e5-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia during pregnancy.
  • OBJECTIVE: To report our experience about a woman with acute promyelocytic leukemia (APL) during pregnancy.
  • PATIENT(S): A 32-year-old-woman, gravida 2, para 1, at the 25th week of pregnancy with a diagnosis of APL.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20447623.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


25. Torres T JP, Concha V E, López G JP, Cofre G J: [Acute retinal necrosis in an acute leukemia pediatric patient]. Rev Chilena Infectol; 2007 Aug;24(4):323-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute retinal necrosis in an acute leukemia pediatric patient].
  • [Transliterated title] Necrosis retinal aguda en un paciente pediátrico con leucemia aguda.
  • Acute retinal necrosis (ARN) is a serious condition that can impair vision.
  • It mostly occurs in adult patients, especially those severely immunocompromised, in association with a reactivation of a herpes virus infection.
  • We present a 4 years old patient with high risk acute leukemia, whom during a course of intense chemotherapy acquired chickenpox with visceral involvement that affected the retina, causing unilateral blindness.
  • [MeSH-major] Chickenpox / complications. Immunocompromised Host. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retinal Necrosis Syndrome, Acute / virology

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728923.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


26. Chandrasekar P: Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation. Med Mycol; 2009;47 Suppl 1:S349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation.
  • Availability of newer, well tolerated anti-Aspergillus drugs at a time of rising prevalence of invasive aspergillosis has sparked enthusiasm for chemoprophylaxis against Aspergillus in allogeneic stem cell recipients.
  • Posaconazole, approved for prophylaxis in allogeneic stem cell recipients with graft versus host disease and in those with acute leukemia, is of promise but has a limitation relating to its oral bioavailability.
  • [MeSH-major] Aspergillosis / prevention & control. Chemoprevention / methods. Stem Cell Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663660.001).
  • [ISSN] 1460-2709
  • [Journal-full-title] Medical mycology
  • [ISO-abbreviation] Med. Mycol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 33
  •  go-up   go-down


27. Azevedo-Silva F, Reis Rde S, Santos Mde O, Luiz RR, Pombo-de-Oliveira MS: Evaluation of childhood acute leukemia incidence and underreporting in Brazil by capture-recapture methodology. Cancer Epidemiol; 2009 Dec;33(6):403-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of childhood acute leukemia incidence and underreporting in Brazil by capture-recapture methodology.
  • Childhood acute lymphoblastic leukemia (ALL) is said to have lower incidence in developing countries, which has implications for its pathogenesis, but there are few studies concerning the completeness of cancer registries in developing countries.
  • This study analyzes the number of cases and incidence of childhood acute lymphoblastic leukemia in three different cities in Brazil and estimates underreporting cases and possible PBCR failures.
  • The sources used were a population-based registry and databases from a diagnosis reference laboratory in 2001 and the Chapman's formula was used to calculate the estimates.
  • CONCLUSIONS: There was a high estimated underreporting of childhood leukemia cases in some Brazilian cities.
  • Childhood acute lymphoblastic leukemia incidence rates are similar to those of developed countries.
  • [MeSH-major] Disease Notification / statistics & numerical data. Population Surveillance. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Epidemiol. 2009 Dec;33(6):401-2 [19932647.001]
  • (PMID = 19833572.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Guan LJ, Zhang JH, Wang YX, Zhang N, Hu YP, Li ZG, Zhao W: [Expression of ubiquitin associated protein 1 gene and tumor-suppressor gene p16 in acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ubiquitin associated protein 1 gene and tumor-suppressor gene p16 in acute leukemia].
  • In order to investigate the expression and the relationship of ubiquitin associated protein 1 (ubap1) gene and tumor-suppressor gene p16 in acute leukemia, 68 cases of acute leukemia and 22 control cases were selected in this experiment, FQ-PCR technique was used to detect the mRNA expression level of ubap1 gene and p16 gene in their bone marrow cells.
  • The results showed that as compared with the control group, the ubap1 gene in acute leukemia group highly expressed (p<0.01), while the p16 gene lowly expressed (p<0.01).
  • In addition to this, the ubap1 gene and p16 gene mRNA expression in AL was not relate with chromosome abnormality (p>0.05).
  • It is concluded that the upregulation of ubap1 gene expression mainly and the downregulation of p16 gene expression mainly may simultaneously participate in the pathogenesis of acute leukemia.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129243.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / UBAP1 protein, human
  •  go-up   go-down


29. Rivera-Del Valle N, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M, Steggerda S, Wheler J, Balasubramanian S, Chandra J: PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. Int J Cell Biol; 2010;2010:207420
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells.
  • In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC inhibitor, require caspase-8 and the adaptor molecule, Fas-associated death domain (FADD), in acute leukemia cells.
  • Taken together, these results provide insight into the mechanism of apoptosis induction by PCI-24781 in leukemia by highlighting the roles of caspase-8, FADD and increased superoxide levels.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12001-8 [11812781.001]
  • [Cites] FEBS J. 2009 Aug;276(15):4256-65 [19583773.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9231-42 [14647441.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1207-14 [15116122.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Cell Death Differ. 2005 Jan;12(1):10-8 [15540114.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2501-6 [16291594.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1309-17 [16731764.001]
  • [Cites] Exp Mol Med. 2006 Dec 31;38(6):616-24 [17202837.001]
  • [Cites] Blood. 2007 Jul 1;110(1):267-77 [17356134.001]
  • [Cites] Nature. 2007 May 24;447(7143):433-40 [17522677.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20 [17594194.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):643-5 [17912024.001]
  • [Cites] Mol Med. 2008 Jan-Feb;14(1-2):20-7 [17973028.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):740-8 [18413789.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19499-510 [18458084.001]
  • [Cites] Antioxid Redox Signal. 2009 May;11(5):1123-37 [19018667.001]
  • [Cites] Blood. 2009 Jul 9;114(2):380-93 [19383971.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3354-65 [19417023.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4512-9 [12920036.001]
  • (PMID = 20145726.001).
  • [ISSN] 1687-8884
  • [Journal-full-title] International journal of cell biology
  • [ISO-abbreviation] Int J Cell Biol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115811
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2817379
  •  go-up   go-down


30. Agarwal R, Gupta R, Bakhshi S, Sharma A: Unusual cytochemical reactivity for toluidine blue in granular acute lymphoblastic leukemia: a report of two rare cases. Turk J Haematol; 2010 Mar 5;27(1):43-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual cytochemical reactivity for toluidine blue in granular acute lymphoblastic leukemia: a report of two rare cases.
  • [Transliterated title] Granüler akut lenfoblastik lösemide toluidin mavisine yönelik olağandışı sitokimyasal reaktivite: İki nadir olgu raporu.
  • Azurophilic granulation of blasts is a feature of acute myeloid leukemia (AML).
  • Granular acute lymphoblastic leukemia (ALL) may mimic AML due to the presence of cytoplasmic granules in lymphoblasts, but cytochemistry and immunophenotyping are helpful in making the correct diagnosis.
  • Immunophenotyping and cytogenetic studies were helpful in making a correct diagnosis.
  • This report of two rare case highlight the reactivity of lymphoblasts with TB not hitherto described and the importance of a detailed diagnostic work-up in acute leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265798.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


31. Hamerschlak N: Leukemia: genetics and prognostic factors. J Pediatr (Rio J); 2008 Aug;84(4 Suppl):S52-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia: genetics and prognostic factors.
  • OBJECTIVE: To present the implications of genetics, particularly of cytogenetic techniques, for the diagnosis and prognosis of leukemia.
  • Nowel and David Hungerford of the 9:22 translocation (the Philadelphia chromosome), genetics has come to play an important role in hematology, in this case making it possible to diagnose chronic myeloid leukemia and opening doors to research avenues for the whole field of oncology.
  • One point of great interest refers to the implications of these findings for the prognosis of a range of types of leukemia.
  • In acute myeloid leukemia, the karyotype is of fundamental importance to postremission treatment decisions, and molecular factors determine the treatment of individuals with normal karyotypes.
  • In chronic myeloid leukemia, clonal evolution is associated with progression to the blast crisis.
  • Finally, in acute lymphoblastic leukemia, factors such as hyperdiploidy and t 12:21 are associated with good prognosis, whereas carriers of t 4:11 and t 9:22 are considered high risk patients.
  • CONCLUSIONS: Genetics has come to stay as far as hematology and, in particular, the management of leukemia and its prognostic factors are concerned.
  • [MeSH-major] Cytogenetic Analysis. Leukemia / genetics
  • [MeSH-minor] Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prognosis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18830516.001).
  • [ISSN] 1678-4782
  • [Journal-full-title] Jornal de pediatria
  • [ISO-abbreviation] J Pediatr (Rio J)
  • [Language] eng; por
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 30
  •  go-up   go-down


32. Loh AH, Chui CH: Port-A-Cath insertions in acute leukaemia and childhood malignancies. Asian J Surg; 2007 Jul;30(3):193-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port-A-Cath insertions in acute leukaemia and childhood malignancies.
  • Incidence of catheter-related bloodstream infections (CRBSIs), other complications and CRBSI-related port removals were analysed for cases with acute leukaemia versus other malignancies.
  • While mean preoperative platelet count was 125.34 x 10(9)/L in children with acute leukaemia and 392.11 x 10(9)/L in those with other malignancies (p < 0.01), the incidence of all complications were similar between both subgroups.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638639.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Zerizer I, Humphries PD: Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 2: imaging of complications of cancer treatment. Cancer Imaging; 2009;9:82-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adolescent cancers are treated with a host of chemotherapy agents, radiotherapy and stem cell transplantation.
  • This second article reviews the imaging of acute and early complications relating to adolescent cancer treatment, many of which may also be seen in the treatment of paediatric patients.
  • [MeSH-minor] Adolescent. Brain / drug effects. Hematopoietic Stem Cell Transplantation / adverse effects. Hepatic Veno-Occlusive Disease / diagnosis. Humans. Infection / diagnosis. Lung / drug effects. Magnetic Resonance Imaging. Osteonecrosis / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2008 Feb;22(2):308-12 [17989709.001]
  • [Cites] Lung Cancer. 2007 Jun;56(3):459-63 [17316891.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] Leukemia. 2001 Jun;15(6):891-7 [11417473.001]
  • [Cites] Bone Marrow Transplant. 2001 Oct;28(7):713-5 [11704797.001]
  • [Cites] Semin Liver Dis. 2002 Feb;22(1):27-42 [11928077.001]
  • [Cites] Abdom Imaging. 2002 Sep-Oct;27(5):523-6 [12172990.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Dec;24(9):746-50 [12468917.001]
  • [Cites] Intern Med. 2003 Jan;42(1):82-7 [12583625.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):229-34 [12688338.001]
  • [Cites] Neurology. 2004 Feb 10;62(3):451-6 [14872029.001]
  • [Cites] Saudi Med J. 2004 Jun;25(6):700-6 [15195196.001]
  • [Cites] Cancer Treat Rep. 1982 Feb;66(2):359-62 [6173124.001]
  • [Cites] AJR Am J Roentgenol. 1982 Sep;139(3):455-61 [6180618.001]
  • [Cites] Hepatology. 1984 Jan-Feb;4(1):116-22 [6363247.001]
  • [Cites] Transplantation. 1987 Dec;44(6):778-83 [3321587.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1699-706 [2213105.001]
  • [Cites] J Thorac Imaging. 1991 Jan;6(1):52-61 [1703580.001]
  • [Cites] Eur J Radiol. 1992 Sep;15(2):107-12 [1425743.001]
  • [Cites] Cancer. 1994 Sep 1;74(5):1627-8 [8062195.001]
  • [Cites] Semin Respir Infect. 1995 Jun;10(2):86-95 [7569403.001]
  • [Cites] Eur Respir J. 2000 Feb;15(2):373-81 [10706507.001]
  • [Cites] Eur J Pediatr Surg. 2000 Oct;10(5):300-3 [11194540.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):331-6 [17455315.001]
  • [Cites] Int Orthop. 1996;20(5):311-4 [8930724.001]
  • [Cites] Clin Radiol. 1999 Jun;54(6):390-7 [10406341.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Dec;26(12):843-6 [15591910.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1588-96 [16026694.001]
  • [Cites] Pediatr Blood Cancer. 2006 Apr;46(4):521-3 [16317738.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Apr;63(5):761-7 [19034447.001]
  • (PMID = 19933021.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  • [Other-IDs] NLM/ PMC2792085
  •  go-up   go-down


34. Tokuda Y, Chinen K, Obara H, Joishy SK: Intervals between symptom onset and clinical presentation in cancer patients. Intern Med; 2009;48(11):899-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We aimed to investigate relative values of the intervals between symptom onset and clinical presentation in cancer patients and to correlate them with diagnosis of distant metastasis.
  • We examined the intervals of symptom onset to clinical presentation and the presence of metastasis at diagnosis.
  • The cancer group with a short interval of only days to weeks included hepatobiliary, ovary, brain, and acute leukemia.
  • CONCLUSION: Hepatobiliary, ovary, brain, and acute leukemia are among the cancer types with an interval of days to weeks, while head and neck, thyroid, and skin cancers are among the types with an interval of months to years.
  • [MeSH-major] Neoplasms / diagnosis. Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / therapy. Registries. Retrospective Studies. Time Factors. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483358.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Sterba J, Prochazka J, Ventruba J, Kren L, Valik D, Burgetova D, Mudry P, Skotakova J, Blatny J: Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia and liver failure. Pediatr Hematol Oncol; 2005 Dec;22(8):649-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia and liver failure.
  • The authors describe an adolescent girl with acute lymphoblastic leukemia (ALL) with subsequent acute liver failure, who developed an aspergillus brain abscess.
  • Her ALL remains now in complete remission 30 months from diagnosis, with no evidence of fungal infection.
  • [MeSH-major] Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspergillosis / drug therapy. Brain Abscess / drug therapy. Liver Failure, Acute / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251170.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  •  go-up   go-down


36. Haresh KP, Joshi N, Gupta C, Prabhakar R, Sharma DN, Julka PK, Rath GK: Granulocytic sarcoma masquerading as Ewing's sarcoma: a diagnostic dilemma. J Cancer Res Ther; 2008 Jul-Sep;4(3):137-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology showed small round cell tumor strongly positive for Monoclonal Imperial Cancer research fund 2 (MIC2) antigen.
  • The initial biopsies were reevaluated with special stains revealing granulocytic sarcomas in acute myeloid leukemia masquerading as Ewing's due to its MIC2 positivity.
  • The possibility of myeloid neoplasms should be considered routinely with known MIC2 positive round cell tumors.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Sarcoma, Ewing / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Elbow / pathology. Flow Cytometry. Humans. Male

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923208.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Inskip PD, Curtis RE: New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer; 2007 Nov 15;121(10):2233-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most common were subsequent primary cancers of the female breast, central nervous system, bone, thyroid gland and soft tissue, as well as cutaneous melanoma and acute non-lymphocytic leukemia (ANLL).
  • The O/E for subsequent ANLL increased with increasing calendar year of initial cancer diagnosis among survivors of cancers other than HL, most likely due to increasing use of leukemogenic drugs for solid cancers and non-Hodgkin lymphoma.
  • Childhood cancer survivors are at markedly increased risk of developing a variety of new cancers relative to the general population, but the magnitude of excess risk and specific types of second cancer vary widely by type of first cancer.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17557301.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


38. Babaei M, Mousavi S, Malek M, Tosi G, Masoumeh Z, Danaei N, Gafar G: Cancer occurrence in Semnan Province, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev; 2005 Apr-Jun;6(2):159-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer occurrence in Semnan Province, Iran: results of a population-based cancer registry.
  • Diagnosis of cancer was based on histopathology, clinical or radiological findings, and death certificates.
  • In the child population the most common tumors were of the brain, acute lymphocytic leukemia, and bone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101326.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


39. Feltbower RG, McNally RJ, Kinsey SE, Lewis IJ, Picton SV, Proctor SJ, Richards M, Shenton G, Skinner R, Stark DP, Vormoor J, Windebank KP, McKinney PA: Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990-2002. Eur J Cancer; 2009 Feb;45(3):420-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990-2002.
  • PATIENTS AND METHODS: Incidence rates were examined by age, sex and period of diagnosis and differences were tested using Poisson regression.
  • RESULTS: 1680 subjects were included comprising 948 leukaemias and 732 lymphomas.
  • Incidence rates for acute lymphoblastic leukaemia were significantly higher for 0-14 compared to 15-24-year-olds, whilst Hodgkin lymphoma showed the reverse.
  • 60% of leukaemia patients aged 15-24 years entered trials compared to 92% of 0-14-year-olds.
  • Survival rates were significantly lower and improved less markedly over time for 15-24 compared to 0-14-year-olds, particularly for leukaemia.
  • [MeSH-major] Leukemia / epidemiology. Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004628.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Reman O, Pigneux A, Huguet F, Vey N, Delannoy A, Fegueux N, de Botton S, Stamatoullas A, Tournilhac O, Buzyn A, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Fière D, Dombret H, Thomas X, GET-LALA group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res; 2008 Nov;32(11):1741-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group.
  • Outcome of adult acute lymphoblastic leukemia (ALL) with central nervous system (CNS) involvement is not clearly defined.
  • We studied 104 patients presenting with CNS involvement at diagnosis among 1493 patients (7%) included into the LALA trials, and 109 patients presenting CNS disease at the time of first relapse among the 709 relapsing patients (15%).
  • Eighty-seven patients (84%) with CNS leukemia at diagnosis achieved complete remission (CR).
  • Fifty-three patients underwent stem cell transplantation (SCT): 25 allogeneic SCT, 28 autologous SCT, while 34 continued with chemotherapy alone.
  • Seven-year overall survival (OS) and disease-free survival (DFS) were 34% and 35%, respectively.
  • There were no significant differences in terms of CR, OS and DFS among patients with CNS involvement at diagnosis and those without CNS disease.
  • Outcome was similar to that of relapsing patients without CNS disease.
  • CNS leukemia in adult ALL is uncommon at diagnosis as well as at the time of first relapse.
  • With intensification therapy, patients with CNS leukemia at diagnosis have a similar outcome than those who did not present with CNS involvement.
  • CNS leukemia at first relapse remains of similar poor prognosis than all other adult ALL in first relapse.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508120.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


41. Ali SH, Yacoub FM, Al-Matar E: Acute lymphoblastic leukemia presenting as bilateral renal enlargement in a child. Med Princ Pract; 2008;17(6):504-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia presenting as bilateral renal enlargement in a child.
  • OBJECTIVE: To report a case with early presentation of acute lymphoblastic leukemia (ALL) as bilateral renal masses and renal failure.
  • Accordingly, bone marrow examination was performed, and diagnosis of ALL was made.
  • The patient developed acute renal failure after initiation of chemotherapy, so he received hemodialysis.
  • [MeSH-major] Acute Kidney Injury / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Renal Dialysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18836283.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


42. Sun HM, Qian SX, Wu YJ, Qiao C, Hong M, Fan L, Yang H, Zhang JF, Zhang SJ, Wu HX, Qiu HX, Lu H, Xu W, Sheng RL, Li JY: [Immunophenotypic features in 143 cases of acute promyelocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb;17(1):176-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotypic features in 143 cases of acute promyelocytic leukemia].
  • This study was aimed to investigate the immunophenotypic characteristics of acute promyelocytic leukemia (APL).
  • 42 patients with HLA-DR(-) (non-APL AML, DR(-)AML) were randomly selected as controls.
  • It is concluded that the immunophenotyping can provide proof to the rapid diagnosis of APL.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236773.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / HLA-DR Antigens; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


43. Chen IM, Chakerian A, Devidas M, Borowitz MJ, Hunger SP, Willman CL, Viswanatha DS: Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method. Br J Haematol; 2006 Nov;135(3):358-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The interpretation of low-level or non-reproducible amplification results in clinical quantitative polymerase chain reaction (Q-PCR) assays can be difficult to definitively resolve.
  • Concerning minimal residual disease detection in leukaemia, indeterminate low-level results might create prognostic or therapeutic dilemmas.
  • We evaluated low-level, ambiguous Q-PCR results in a study of paired diagnostic and end-induction (day 29) TEL-AML1 positive acute lymphoblastic leukaemia samples utilising a novel fluorescent primer ligation detection assay.
  • The data presented here indicate that a significant number of low-level apparent Q-PCR positive results may be spurious or non-specific in nature, requiring additional technical manoeuvres for confirmation of true positive cases.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. DNA Primers / chemistry. DNA, Neoplasm / chemistry. Flow Cytometry / methods. Fluorescent Dyes. Humans. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Reproducibility of Results

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984387.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA98543-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Fluorescent Dyes; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


44. Lim CK, Goh YT, Hwang WY, Ho LP, Sun L: Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore. Biomark Insights; 2007 Aug 08;2:293-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore.
  • Biomarkers provide certain values for diagnosis, monitor treatment efficacy, or for the development of novel therapeutic approach for particular diseases.
  • Thus, the identification of specific of biomarkers for specific medical problems, including malignant diseases may be valuable in medical practice.
  • In the study, we have used the Wilms' tumor gene (WT1) as a biomarker to evaluate its expression in local adult patients with newly diagnosed acute leukemia, including both acute myeloid and lymphoid leukemias (AML and ALL).
  • AIM: To investigate WT1 gene expression in adult patients with acute leukemia at diagnosis.
  • METHODS: Eighteen patients with acute leukemia diagnosed at Singapore General Hospital, Singapore, between September, 2004 and July, 2005 were included in this study.
  • RESULTS: WT1 gene was exclusively expressed in all eighteen, including three ALL and fifteen AML, patients.
  • CONCLUSIONS: WT1 gene expression was observed in local patients with acute leukemia at diagnosis.
  • It may be used as a potential molecular marker for diagnosis, clinical progression of the diseases or monitoring the response to treatment, as well as a target for the development of novel therapeutic approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1990 Feb 22;343(6260):774-8 [2154702.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] Blood. 2003 Jul 15;102(2):773-4; author reply 774 [12835231.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3835-7 [12411326.001]
  • [Cites] Int J Hematol. 2002 Aug;76(2):103-9 [12215007.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Aug;11(4):589-99 [12201948.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1167-71 [12006533.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):197-209 [11226170.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):921-5 [11221883.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2198-203 [10733485.001]
  • [Cites] Blood. 2000 Jan 1;95(1):286-93 [10607714.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28122-30 [16698800.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1293-8 [16533527.001]
  • [Cites] Nucl Recept Signal. 2003;1:e012 [16604184.001]
  • [Cites] Methods Mol Med. 2006;125:199-211 [16502587.001]
  • [Cites] Arch Pharm Res. 2006 Jan;29(1):80-7 [16491848.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):595-9 [16471322.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1405-12 [9028964.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Oncogene. 1996 Mar 7;12(5):1005-14 [8649791.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3071-9 [7949179.001]
  • [Cites] Leukemia. 1992 May;6(5):405-9 [1317488.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • (PMID = 19662212.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717842
  • [Keywords] NOTNLM ; HLA-A / WT1 / adulthood acute leukemia / gene expression
  •  go-up   go-down


45. Van Den Akker J, Coppo P, Portnoï MF, Barbu V, Bories D, Gorin NC: Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia. Leuk Lymphoma; 2007 Sep;48(9):1858-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia.
  • A 31-year-old patient developed chronic myelogenous leukemia (CML) in November, 1983.
  • In November 1984, following a diagnosis of acceleration, he received an autologous hemopoietic transplant after conditioning with cyclophosphamide and total body irradiation.
  • Multiple nonrecurrent clonal chromosomal abnormalities appeared leading to a very complex karyotype, including among others involvement of chromosomes 1, 7, 9, 13, 19, and X.
  • Acute myeloid crisis was diagnosed in February, 2004.
  • We question whether the ex vivo purging procedure with mafosfamide has favored the occurrence of these particular cytogenetic abnormalities (with no independent oncogenic potential) within the original leukemic stem cell pool.
  • At time of acute crisis, the dramatic response to imatinib mesylate leading to a complete cytogenetic and molecular response is noteworthy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Chromosome Aberrations. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Philadelphia Chromosome. Piperazines / therapeutic use. Pyrimidines / therapeutic use


46. Kaminska D, Bernat B, Vakulenko O, Kuzniar J, Tyran B, Suchnicki K, Lange A, Mazanowska O, Halon A, Klinger M: Glomerular lesion and increased cytokine gene expression in renal tissue in patients with decompensated nephrotic syndrome due to chronic GvHD. Ren Fail; 2010 May;32(4):510-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nephrotic syndrome is a rare complication of allogeneic stem cell transplantation (alloHSCT).
  • We present two cases of nephrotic syndrome during chronic graft-versus-host disease (GvHD) involving altered cytokine gene expression in renal tissue.
  • A patient with acute lymphatic leukemia demonstrated nephrotic syndrome due to minimal change disease as a marker of chronic GvHD.
  • A patient with acute lymphoblastic leukemia suffered from severe nephrotic syndrome due to membranous glomerulopathy.
  • [MeSH-major] Cytokines / genetics. Graft vs Host Disease / complications. Nephrosis, Lipoid / etiology. Nephrotic Syndrome / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Gene Expression. Humans. Male. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446793.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


47. Kwon WK, Lee JY, Mun YC, Seong CM, Chung WS, Huh J: Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach. Korean J Hematol; 2010 Sep;45(3):171-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.
  • METHODS: Bone marrow aspirates were obtained from 135 patients at diagnosis (56 AML, 32 MDS, 20 ALL, and 27 MM) between 2005 and 2010.


48. LoSavio AD, Bunnag AP, Rubin DT: Colonic infiltration with chronic myelomonocytic leukemia. Nat Clin Pract Gastroenterol Hepatol; 2007 Apr;4(4):229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic infiltration with chronic myelomonocytic leukemia.
  • BACKGROUND: A 75-year-old female presented with a 1 month history of non-bloody diarrhea, associated with abdominal cramping and urgency.
  • Her medical history was notable for chronic myelomonocytic leukemia, diagnosed 6 years previously and managed expectantly by monitoring the patient's complete blood count.
  • The patient's course of disease was ultimately complicated by acute disseminated encephalomyelitis and death.
  • DIAGNOSIS: Leukemic colitis.
  • MANAGEMENT: Management of underlying leukemia with systemic hydroxyurea and topical colonic 5-aminosalicylic acid therapy.
  • [MeSH-major] Colon / pathology. Leukemia, Myelomonocytic, Chronic / complications. Leukemia, Myelomonocytic, Chronic / pathology. Leukemic Infiltration / diagnosis
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Aged. Biopsy, Needle. Colitis / etiology. Colitis / pathology. Colitis / therapy. Colonoscopy / methods. Diarrhea / diagnosis. Diarrhea / etiology. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Severity of Illness Index

  • Genetic Alliance. consumer health - Chronic Myelomonocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17404590.001).
  • [ISSN] 1743-4386
  • [Journal-full-title] Nature clinical practice. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Clin Pract Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Winterstein AR, Bohndorf K, Vollert K, Wagner T, Gnekow A, Roemer FW: Invasive aspergillosis osteomyelitis in children--a case report and review of the literature. Skeletal Radiol; 2010 Aug;39(8):827-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The case of a 4-year-old boy is presented who developed lumbalgia and thigh pain during ongoing chemotherapy for acute lymphatic leukemia.
  • The histologic diagnosis was consistent with angioinvasive aspergillosis.
  • [MeSH-major] Aspergillosis. Femur / diagnostic imaging. Lumbar Vertebrae / diagnostic imaging. Osteomyelitis / diagnosis. Pancytopenia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Pain. Radiography. Ultrasonography

  • Genetic Alliance. consumer health - Osteomyelitis.
  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kurume Med J. 1999;46(1):87-90 [10319618.001]
  • [Cites] Clin Infect Dis. 2008 Jun 15;46(12):1813-21 [18462102.001]
  • [Cites] J Bone Joint Surg Br. 1985 Nov;67(5):800-3 [3902849.001]
  • [Cites] Br J Radiol. 1977 Dec;50(600):918-20 [338084.001]
  • [Cites] Pediatr Radiol. 2003 Jul;33(7):453-60 [12739082.001]
  • [Cites] Infect Dis Clin North Am. 2006 Dec;20(4):789-825 [17118291.001]
  • [Cites] Clin Microbiol Infect. 2008 May;14 Suppl 4:37-45 [18430128.001]
  • [Cites] Infection. 2003 Mar;31(2):121-4 [12682820.001]
  • [Cites] Clin Infect Dis. 1999 Jun;28(6):1223-9 [10451157.001]
  • [Cites] Diagn Microbiol Infect Dis. 2009 Apr;63(4):384-7 [19249181.001]
  • [Cites] J Bone Joint Surg Am. 1991 Jan;73(1):37-51 [1985993.001]
  • [Cites] Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5 [9564455.001]
  • [Cites] AJR Am J Roentgenol. 2002 Feb;178(2):319-25 [11804886.001]
  • [Cites] J Bone Joint Surg Am. 1969 Dec;51(8):1573-83 [4901855.001]
  • [Cites] Rev Infect Dis. 1990 Nov-Dec;12(6):1147-201 [2267490.001]
  • [Cites] J Infect. 2000 Jul;41(1):97-100 [11041713.001]
  • [Cites] J Pathol Bacteriol. 1965 Jan;89:391-5 [14263488.001]
  • [Cites] Pediatr Radiol. 2008 Jun;38(6):709-12 [18392819.001]
  • [Cites] N Engl J Med. 2009 Apr 30;360(18):1870-84 [19403905.001]
  • [Cites] Pediatrics. 1994 May;93(5):830-5 [8165091.001]
  • [Cites] Surg Neurol. 2004 Jun;61(6):551-5; discussion 555 [15165794.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):183-93 [18231904.001]
  • [Cites] Clin Radiol. 2004 Dec;59(12 ):1079-93 [15556590.001]
  • [Cites] Pediatr Neurosurg. 2001 Jul;35(1):18-23 [11490186.001]
  • [Cites] Orthopade. 2004 Mar;33(3):273-86 [15007552.001]
  • [Cites] Singapore Med J. 2009 Apr;50(4):e151-4 [19421672.001]
  • [Cites] Clin Infect Dis. 2007 Jun 1;44(11):1524-5 [17479958.001]
  • [Cites] Clin Infect Dis. 2001 Jan;32(1):9-16 [11112668.001]
  • (PMID = 20512571.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


50. Franklin JG, Paus MD, Pluetschow A, Specht L: Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev; 2005;(4):CD003187
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.
  • BACKGROUND: Second malignancies (SM) are a major late effect of treatment for Hodgkin's disease (HD).
  • OBJECTIVES: Radiotherapy (RT), chemotherapy (CT) and combined chemo-radiotherapy (CRT) for newly-diagnosed Hodgkin's disease are compared with respect to SM risk, overall (OS) and progression-free (PFS) survival.
  • Secondary acute leukemia (AL), non-Hodgkin's lymphoma (NHL) and solid tumours (ST) were also analysed separately.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235316.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 127
  •  go-up   go-down


51. Fanci R, Pecile P, Di Lollo S, Dini C, Bosi A: Pulmonary mucormycosis with cervical lymph node involvement in a patient with acute myeloid leukaemia: a case report. Mycoses; 2008 Jul;51(4):354-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary mucormycosis with cervical lymph node involvement in a patient with acute myeloid leukaemia: a case report.
  • Here we describe a rare case of pulmonary mucormycosis and simultaneous cervical lymphadenitis in a patient with acute myeloid leukaemia.
  • The diagnosis of Mucor is very difficult, especially in severely immunocompromised patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / microbiology. Lymphadenitis / microbiology. Mucormycosis / diagnosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855847.001).
  • [ISSN] 1439-0507
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / liposomal amphotericin B; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


52. Mlombie Y: Acute leukemia and aggressive lymphoma treatment in adults: it is time for Malawi to move forward. Malawi Med J; 2010 Jun;22(2):59-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia and aggressive lymphoma treatment in adults: it is time for Malawi to move forward.
  • [MeSH-major] Burkitt Lymphoma. Leukemia
  • [MeSH-minor] Acute Disease. Humans. Malawi. Practice Patterns, Physicians' / trends

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1975 Feb;19(2):201-8 [1240046.001]
  • [Cites] S Afr Med J. 2009 Apr;99(4):243-8 [19588777.001]
  • [CommentOn] Malawi Med J. 2009 Jun;21(2):86, 88-9 [20345012.001]
  • (PMID = 21618748.001).
  • [ISSN] 1995-7262
  • [Journal-full-title] Malawi medical journal : the journal of Medical Association of Malawi
  • [ISO-abbreviation] Malawi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Malawi
  • [Other-IDs] NLM/ PMC3345756
  •  go-up   go-down


53. Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM: Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol; 2007 Mar;18(3):535-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.
  • BACKGROUND: Controversy exists regarding the role of high-dose therapy followed by stem-cell transplant (SCT) in the treatment of T-cell lymphoblastic lymphoma (T-LBL).
  • Treatment, before planned SCT, consisted of a non-Hodgkin's lymphoma (NHL)/acute lymphoblastic leukemia hybrid chemotherapy protocol (28 patients) or a standard NHL chemotherapy regimen (six patients).
  • All patients who received allografts are alive without disease at 38-141 months since diagnosis.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17158775.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Rossi S, Canal F, Licci S, Zanatta L, Laurino L, Gottardi M, Gherlinzoni F, Dei Tos AP: Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy. Hum Pathol; 2009 Jul;40(7):1040-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopic examination of the bone marrow biopsy revealed dysplastic features, with abnormal localization of immature precursors and micromegakaryocytes, and islands of undifferentiated oval small/medium-size cells, suggestive of acute myeloid leukemia arising in the setting of a myelodysplastic syndrome.
  • Cytogenetic analyses of bone marrow aspirate disclosed the presence of 2 different rearrangements, subsequently confirmed by fluorescent in situ hybridization and was crucial in making the correct diagnosis.
  • [MeSH-minor] Adult. Anemia, Refractory / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Cells / pathology. Chromosomes, Human, Pair 11. Combined Modality Therapy / adverse effects. Female. Humans. Leukemia, Myeloid, Acute / pathology. Soft Tissue Neoplasms / pathology. Thigh / pathology


55. Thomas X, Campos L, Le QH, Guyotat D: Heat shock proteins and acute leukemias. Hematology; 2005 Jun;10(3):225-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat shock proteins and acute leukemias.
  • HSPs have also been implicated in the resistance of leukemia cells to potential therapeutic agents.
  • HSPs were shown highly expressed by acute myeloid leukemia (AML) cells as well as by acute lymphoblastic leukemia (ALL) cells.
  • [MeSH-major] Antineoplastic Agents / metabolism. Gene Expression Regulation, Leukemic / drug effects. HSP90 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Rifabutin / analogs & derivatives

  • Hazardous Substances Data Bank. RIFABUTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019471.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / Neoplasm Proteins; 1W306TDA6S / Rifabutin; 4GY0AVT3L4 / tanespimycin
  • [Number-of-references] 122
  •  go-up   go-down


56. Kasahara S, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Yamada T, Sawada M, Takahashi T, Moriwaki H: [Clinical effects of biapenem on febrile neutropenia in patients with hematological malignancy]. Jpn J Antibiot; 2008 Jun;61(3):115-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When the diagnosis of FN was established among them, those patients received intravenous biapenem 0.6 g every 12 hours.
  • The underlying diseases were acute lymphocytic leukemia in 6 cases, acute myelocytic leukemia in 21, multiple myeloma in 3, and non-Hodgkin's lymphoma in 19.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Leukemia, Myeloid, Acute / complications. Lymphoma, Non-Hodgkin / complications. Multiple Myeloma / complications. Neutropenia / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Thienamycins / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814798.001).
  • [ISSN] 0368-2781
  • [Journal-full-title] The Japanese journal of antibiotics
  • [ISO-abbreviation] Jpn J Antibiot
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Thienamycins; 120410-24-4 / biapenem
  •  go-up   go-down


57. Ennis MK, Dingli D: Death by fusion for acute leukemia cells. Cancer Biol Ther; 2010 Mar 1;9(5):358-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death by fusion for acute leukemia cells.
  • [MeSH-major] Leukemia / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Biol Ther. 2010 Mar 1;9(5):350-7 [20061812.001]
  • (PMID = 20104027.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


58. Li R, Cao XH, Liu C, Wu XL, Ling YW, Zhang Y, Feng R, Liu QF: [Clinical implications of HLA-G protein expression in acute leukemia]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov;30(11):2446-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical implications of HLA-G protein expression in acute leukemia].
  • OBJECTIVE: To detect the expression of membrane-bound HLA-G (mHLA-G) and serum HLA-G (sHLA-G) in acute leukemia patients and investigate the correlation between HLA-G expression and the occurrence and development of acute leukemia.
  • METHODS: Enzyme-linked immunosorbent assay and flow cytometry were used to detect the expression levels of sHLA-G and mHLA-G in 40 newly diagnosed leukemia cases, 10 refractory and relapsed leukemia cases, and 30 leukemia cases receiving chemotherapy.
  • RESULTS: The mean serum level of sHLA-G in normal individuals was 5.87±2.07 ng/ml, as compared to 10.05±6.58 ng/ml in newly diagnosed leukemia patients and 12.32±5.85 ng/ml in refractory and relapsed cases.
  • CONCLUSION: HLA-G expression levels might influence the treatment outcomes and can serve as a prognostic factor for acute leukemia.
  • [MeSH-major] HLA-G Antigens / metabolism. Leukemia / metabolism. Leukemia / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21097401.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA-G Antigens
  •  go-up   go-down


59. van Onna M, van Bemmel T, van Wensen E, Schaar C, Slis H, Spronk PE: Black and blue . . . and unconscious. BMJ; 2009;339:b2864
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Injuries / diagnosis. Coma / etiology. Leukemia, Myeloid, Acute / diagnosis. Purpura / etiology
  • [MeSH-minor] Adult. Cerebral Hemorrhage / diagnosis. Cerebral Hemorrhage / etiology. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Coma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625351.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Li X, Du W, Liu W, Li X, Li H, Huang SA: Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS; 2010 May;118(5):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
  • Multiparameter flow cytometry (MFC) plays a vital role in the detection of minimal residual disease (MRD) and diagnosis of relapse in acute leukemia.
  • However, application of a limited panel of antibodies in MFC leads to high rates of false-negative and false-positive results.
  • Thirteen patients with acute lymphoblastic leukemia (ALL) and 12 patients with acute myeloid leukemia (AML) were immunophenotyped by MFC at diagnosis and at relapse using a comprehensive panel of monoclonal antibodies (McAbs) to 27 antigens and CD45/SSC gating.
  • In 23 of 25 patients (92.3%), changes in at least one of progenitor-associated, myeloid and lymphoid antigens between diagnosis and relapse were observed.
  • Multiple panels of three or more McAbs are likely to be required in the monitoring of MRD and diagnosis of relapse in acute leukemia by MFC.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477810.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm
  •  go-up   go-down


61. Cwiklińska M, Balwierz W: [Osteoarticular pains as early manifestation of malignancies in children]. Przegl Lek; 2009;66(1-2):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When these complaints predominate in the clinical presentation, they lead the diagnosis towards nonmalignant conditions, that are most common cause of such symptoms in children, like injuries, nonspecific reactive arthritis or inflammatory connective tissue diseases.
  • However, in acute lymphoblastic leukaemia, the most prevalent childhood malignancy, bone and joint pains are present early in 40-60% of cases and they frequently anticipate any abnormalities in complete blood counts.
  • Findings reported in the literature and own observations indicate that these complaints correlate with: lower white cell counts, lower percentage of blast cells in the peripheral blood and lower incidence of organomegaly - that may delay the decision of bone marrow aspiration.
  • Oncologic vigilance must be inspired by discreet hematological abnormalites (like increased anemia, lower white cell counts with lymphocytosis, mild thrombocytopenia) -that indicate bone marrow infiltration, as well as high erythrocyte sedimentation rate, accompanied by moderately elevated C-reactive protein - characteristic for malignancy.
  • The aim of this study was to focus the attention of pediatricians to the necessity of including malignancy in the differential diagnosis of intensive or unexplained osteoarticular complaints.
  • [MeSH-major] Arthralgia / etiology. Arthritis / etiology. Neoplasms / complications. Neoplasms / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19485254.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


62. Inoue D, Maruoka H, Takahashi T: Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometry. Mediterr J Hematol Infect Dis; 2010;2(2):e2010020
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometry.
  • BACKGROUND: Although several prognostic indicators of de novo acute myeloid leukemia (AML) patients have been identified, the clinical significance of minimal residual disease (MRD) needs to be evaluated further in Japanese adult patients.
  • METHODS: Using three color flow cytometry, we identified leukemia-associated phenotypes (LAP) in bone marrow specimens at diagnosis and assessed the relationship between clinical outcomes and the presence of marrow MRD in 33 patients who achieved a morphologic complete remission (CR) and were followed after CR.
  • Four patients in Group A underwent allogeneic hematopoietic stem-cell transplantation (HSCT) when in the CR state and did not experience relapse at a median follow-up period of 20.5 months after HSCT.
  • CONCLUSIONS: MRD is critical for predicting de novo AML outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hematother Stem Cell Res. 2002 Apr;11(2):349-57 [11983106.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):160-2 [12126839.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3078-85 [15284114.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1103-8 [16541144.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1783-9 [16838027.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:156-61, 514 [17124055.001]
  • [Cites] Leukemia. 2007 May;21(5):998-1004 [17361227.001]
  • [Cites] Clin Chim Acta. 2008 Sep;395(1-2):120-3 [18590714.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4944-51 [18606980.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):388-400 [18692689.001]
  • [Cites] Am J Clin Pathol. 2009 Jan;131(1):16-26 [19095561.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2465-70 [9310499.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):243-52 [14531905.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:82-101 [14633778.001]
  • [Cites] Acta Haematol. 2004;112(1-2):55-67 [15179005.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1380-90 [15201848.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2434-41 [16638849.001]
  • [Cites] Am J Clin Pathol. 2008 Jun;129(6):934-45 [18480011.001]
  • [Cites] Cytometry B Clin Cytom. 2009 Mar;76(2):91-101 [18727068.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1212-5 [1878588.001]
  • [Cites] Br J Haematol. 2009 Feb;144(4):517-23 [19055671.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3948-52 [11090082.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1746-51 [11535507.001]
  • (PMID = 21415971.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033143
  •  go-up   go-down


63. Xu Q, Wang M, You Q, Wang H, Ye K, Zhan R, Zhou Y: Isolated recurrence of granulocytic sarcoma-two case reports-. Neurol Med Chir (Tokyo); 2009 Dec;49(12):611-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 29-year-old male presented with an extra- and intracranial mass 10 years after bone marrow transplantation for chronic myeloid leukemia.
  • A 34-year-old female presented with an intracranial mass 3 years after complete remission of acute myeloid leukemia-M2a.
  • The second patient only received whole brain radiotherapy, failed to respond, and died of systemic leukemia later.
  • [MeSH-major] Head and Neck Neoplasms / etiology. Head and Neck Neoplasms / pathology. Leukemia, Myeloid, Acute / complications. Neoplasm Recurrence, Local / pathology. Sarcoma, Myeloid / etiology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Brain Neoplasms / etiology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Combined Modality Therapy / methods. Drug Therapy. Early Diagnosis. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Radiotherapy. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035140.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Dubowy R, Graham M, Hakami N, Kletzel M, Mahoney D, Newman E, Ravindranath Y, Camitta B: Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. J Pediatr Hematol Oncol; 2008 May;30(5):353-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.
  • At concentrations >0.1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro.
  • This study of children with refractory acute leukemia was designed to take advantage of this biochemical modulation.
  • Thirty-three children [26 acute lymphocytic leukemia (ALL), 7 acute nonlymphocytic leukemia] were treated; 29 received at least 1 full course.
  • There were 6 complete responses (5 ALL), 5 partial responses (3 ALL), and 19 patients with no response or progressive disease.
  • This combination of HU and ara-C is tolerable and has efficacy in refractory leukemias.
  • [MeSH-major] Cytarabine / toxicity. Hydroxyurea / toxicity. Leukemia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Infection / epidemiology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality. Liver / drug effects. Liver / pathology. Skin / drug effects. Skin / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458568.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ NIHMS721202; NLM/ PMC4601800
  •  go-up   go-down


65. Berköz M, Yalin S: Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility. Leuk Res; 2009 Jul;33(7):919-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility.
  • In this study, we aimed to determine whether any association exists between genetic polymorphism in CYP2B6G15631T and individual susceptibility to acute leukemia.
  • Our study group consisted of 80 acute leukemia patients and 100 unrelated healthy volunteers as a control group.
  • 44 of the acute leukemia patients were diagnosed with acute lymphoblastic leukemia (ALL) and 36 patients with acute myeloid leukemia (AML).
  • The frequencies of GG genotype (wild type) were 40.9%, 50% and 67% in ALL, AML and control groups, respectively.
  • The TT genotype (homozygous variant) was not observed in either control or leukemia cases.
  • Logistic regression analyses showed a significant correlation between the CYP2B6 G15631T polymorphism (GT) and acute leukemia patients (OR=2.481, 95% CI=1.353-4.551, p=0.003).
  • Our findings indicate that GT genotype may be an important genetic determinant for acute leukemias.
  • According to our knowledge, this is the first report of an association between acute leukemia cases and the CYP2B6 G15631T polymorphism.
  • [MeSH-major] Aryl Hydrocarbon Hydroxylases / genetics. Leukemia, Myeloid, Acute / genetics. Oxidoreductases, N-Demethylating / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Cytochrome P-450 CYP2B6. DNA, Neoplasm / genetics. Disease Susceptibility. Genotype. Humans. Middle Aged. Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144407.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2B6 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2B6; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


66. Son MH, Park ES, Seo JH, Lim JY, Park CH, Woo HO, Youn HS: Staphylococcal endocarditis presenting with a renal infarct in a patient with acute lymphoblastic leukemia. Cancer Res Treat; 2008 Sep;40(3):151-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staphylococcal endocarditis presenting with a renal infarct in a patient with acute lymphoblastic leukemia.
  • We present here a patient with acute lymphoblastic leukemia (ALL) and who developed infective endocarditis during induction chemotherapy with prednisolone, L-asparaginase (Leunase), vincristine and adriamycin.
  • The patient did not have a history of a central venous catheter.
  • Consequently, ten days after the diagnosis of infective endocarditis, a successful mitral valvuloplasty was performed without complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2002 Oct 15;186(8):1145-54 [12355366.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):508-16 [12518376.001]
  • [Cites] Infect Immun. 2004 Jul;72(7):4322-6 [15213184.001]
  • [Cites] J Clin Invest. 1984 Jun;73(6):1750-3 [6427279.001]
  • [Cites] J Am Coll Cardiol. 1989 Sep;14(3):631-8 [2768712.001]
  • [Cites] Thorac Cardiovasc Surg. 1991 Oct;39(5):273-80 [1785114.001]
  • [Cites] Infect Immun. 2002 Jun;70(6):3033-9 [12010995.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):489-96 [10048421.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1993 Nov;15(4):400-5 [8214362.001]
  • [Cites] Circulation. 2005 Jun 14;111(23):e394-434 [15956145.001]
  • [Cites] Eur Heart J. 2001 May;22(10):874-8 [11350097.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2001 Feb;20(2):117-9 [11305464.001]
  • [Cites] Ann Hematol. 2005 Jun;84(6):395-9 [15735962.001]
  • (PMID = 19688123.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2697465
  • [Keywords] NOTNLM ; Coagulation / Precursor cell lymphoblastic leukemia-lymphoma / Staphylococcus aureus / Vegetation
  •  go-up   go-down


67. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • Eleven patients were alive with no evidence of disease at last follow-up, and 1 patient was alive with clinical evidence of pulmonary metastasis.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


68. Stabell N, Nordal E, Stensvold E, Gammelsrud KW, Lund B, Taxt A, Buhring F, Greve-Isdahl M, Fornebo HP, Simonsen GS, Klingenberg C: Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis; 2008;40(4):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute lymphoblastic leukaemia was the most common diagnosis (49 patients).
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bacterial Infections / drug therapy. Bacterial Infections / microbiology. Child. Child, Preschool. Female. Gram-Negative Bacteria / drug effects. Gram-Positive Bacteria / drug effects. Humans. Incidence. Male. Norway / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Fever.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17918015.001).
  • [ISSN] 0036-5548
  • [Journal-full-title] Scandinavian journal of infectious diseases
  • [ISO-abbreviation] Scand. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


69. Herry A, Douet-Guilbert N, Guéganic N, Morel F, Le Bris MJ, Berthou C, De Braekeleer M: Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association. Ann Hematol; 2006 Apr;85(4):244-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association.
  • We report here a 71 year-old female presenting with acute myeloblastic leukemia (FAB-M1) after treatment of essential thrombocythemia with Vercyte.
  • Twenty-one cases, including ours, of myelodysplastic syndromes and acute myelogenous leukemia with MLL amplification present in hsr or dmin were found in the literature.
  • Most of these patients shared some characteristics: they were old, they had de novo acute myeloid leukemia (AML) with a complex karyotype and a short survival, 90% of them having also a del(5q).
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 5 / genetics. Chromosomes, Human, Pair 7 / genetics. Gene Amplification. Leukemia, Myeloid, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Aged. Cytogenetic Analysis. Fatal Outcome. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence / methods. Karyotyping. Pipobroman / therapeutic use. Prognosis. Sensitivity and Specificity. Thrombocytosis / diagnosis. Thrombocytosis / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PIPOBROMAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425025.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 6Q99RDT97R / Pipobroman; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


70. Pinheiro RF, Serio FM, Silva MR, Briones MR, Chauffaille ML: Association of loss of heterozygosity with cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome. Braz J Med Biol Res; 2008 Jul;41(7):610-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of loss of heterozygosity with cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome.
  • Deletions on chromosomes 5 and 7 are frequently seen in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
  • We evaluated loss of heterozygosity (LOH) in 44 patients (18 MDS and 26 AML, diagnosed according to WHO classification criteria) at diagnosis, using a four-microsatellite marker panel: an intragenic marker on the 7th intron of gene IRF-1 of the 5q31.1 region and three markers located inside the 7q31.1 region and correlated the LOH with karyotype abnormalities.


71. Szpecht D, Derwich K, Wachowiak J, Konatkowska B, Dworacki G: [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1041-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
  • We report a case of a 4-year-old girl with diagnosed proB acute lymphoblastic leukaemia with co-expression CD33 antigen, treated according to Acute Lymphoblastic Leukaemia Intercontinental - Berlin Frankfurt Münster 2002 (ALL-IC BFM 2002) protocol for standard risk group.
  • The late isolated bone marrow relapse of acute myeloid leukaemia, type 7 was noted in our patient.
  • We recognized this case as a lineage switch acute lymphoblastic leukaemia to acute myeloid leukaemia.
  • In spite of Ida Flag regimen and following Acute Myeloid Leukaemia - Berlin Frankfurt Münster 2004 (AML-BFM 2004) protocol were administered, the clinical and haematological remission was not achieved and the patient died because of disease progression (circulatory and respiratory insufficiency).
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Cell Lineage. Cell Transformation, Neoplastic. Child, Preschool. Daunorubicin / therapeutic use. Disease Progression. Fatal Outcome. Female. Humans. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531823.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


72. Blalock WL, Bavelloni A, Piazzi M, Faenza I, Cocco L: A role for PKR in hematologic malignancies. J Cell Physiol; 2010 Jun;223(3):572-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although a subset of myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia contain low levels of PKR expression and activity, elevated PKR activity and/or expression have been detected in a wide range of hematologic malignancies, from bone marrow failure disorders to acute leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20232306.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / eIF-2 Kinase
  •  go-up   go-down


73. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol; 2010 May 20;28(15):2625-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Incidence and survival data for childhood cancers came from the Surveillance, Epidemiology, and End Results 9 (SEER 9) registries, and mortality data were based on deaths in the United States that were reported by states to the Centers for Disease Control and Prevention by underlying cause.
  • RESULTS: Childhood cancer incidence rates increased significantly from 1975 through 2006, with increasing rates for acute lymphoblastic leukemia being most notable.
  • For leukemias and lymphomas, significantly decreasing mortality rates were observed throughout the 32-year period, though the rate of decline slowed somewhat after 1998.
  • Increased survival rates were observed for all categories of childhood cancers studied, with the extent and temporal pace of the increases varying by diagnosis.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3004-11 [10944134.001]
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2011-8 [12743156.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2873-6 [15254055.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1072-80 [15329918.001]
  • [Cites] Cancer. 1976 Aug;38(2):633-46 [184912.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):293-8 [71004.001]
  • [Cites] Cancer. 1981 May 1;47(9):2302-11 [6164480.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):349-60 [2544249.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Blood. 1994 Jul 15;84(2):570-3 [8025282.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):526-33 [9324339.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):237-45 [9440748.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3744-51 [9850017.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):13-20 [15534881.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):166-73 [16029445.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1928-34 [16103439.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2352-8 [16710034.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):1961-71 [16919764.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Lancet. 2007 Jun 23;369(9579):2106-20 [17586306.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):894-900 [17584910.001]
  • [Cites] Leukemia. 2008 Jan;22(1):189-93 [17690702.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Feb;14(2):137-80 [18215777.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1859-67 [18076067.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1169-75 [18293379.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2384-9 [18467730.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1646-54 [18502832.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 17;100(18):1301-9 [18780868.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):261-7 [18759768.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1034-40 [19171711.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1007-13 [19171716.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2658-70 [19173295.001]
  • (PMID = 20404250.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881732
  •  go-up   go-down


74. Kalmanti L, Dampaki K, Dimitriou H, Stiakaki E, Chaniotis V, Stathopoulos E: A morphometric approach for the evaluation of angiogenesis in acute lymphoblastic leukemia of childhood. Leuk Res; 2005 Jun;29(6):673-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A morphometric approach for the evaluation of angiogenesis in acute lymphoblastic leukemia of childhood.
  • Angiogenesis was estimated in childhood acute lymphoblastic leukemia (ALL) by the use of a novel morphometric method.
  • According to our results both MVD and VC-MVDI were increased at diagnosis of ALL in comparison with the control group.
  • Therefore, VC-MVDI could be more representative of the true increase of angiogenesis, correlating better with the outcome of the disease.
  • [MeSH-major] Bone Marrow Cells / pathology. Neovascularization, Pathologic / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis


75. Chen XW, Yue LJ, Li CG, Li CR, Zhang M, Shi HS: [Polymorphisms of thymidylate synthase gene detected by RT-PCR-denaturing gradient gel electrophoresis in children with acute leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr;11(4):251-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polymorphisms of thymidylate synthase gene detected by RT-PCR-denaturing gradient gel electrophoresis in children with acute leukemia].
  • This study investigated the allelic frequencies and distribution characters of single-nucleotide polymorphisms within the coding region (cSNPs) of TS gene in Chinese children with acute leukemia (AL) and normal control children in order to explore the possible relationship between the cSNP in human TS gene and chemotherapeutic effects of 5-fluorouracils.
  • [MeSH-major] Leukemia / genetics. Polymorphism, Single Nucleotide. Reverse Transcriptase Polymerase Chain Reaction / methods. Thymidylate Synthase / genetics
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Electrophoresis, Polyacrylamide Gel. Female. Humans. Infant. Infant, Newborn. Male. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374805.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


76. Hsiao HH, Sashida G, Ito Y, Kodama A, Fukutake K, Ohyashiki JH, Ohyashiki K: Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10). Cancer Genet Cytogenet; 2006 Mar;165(2):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10).
  • We analyzed 23 patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) showing a der(1;7)(q10;p10) [hereafter der(1;7)] to identify the exact predictive factor of this cytogenetic change.
  • Eight (34.8%) patients, including six with MDS and two with AML patients, had a previous history of genotoxic exposure, especially radiation and/or antimetabolites.
  • Patients with der(1;7) consisted of three groups: one third of patients had a previous history of genotoxic agents, one third had additional cytogenetic changes at the time of MDS/AML diagnosis without previous exposure history, and the remaining one third had neither a previous exposure history nor additional cytogenetic changes.
  • Identification of prognostic disadvantage might be required for applying the appropriate strategy in managing MDS/AML patients with rare der(1;7) abnormality.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 7. Leukemia, Myeloid / genetics. Mutagens / toxicity. Myelodysplastic Syndromes / genetics
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis


77. Liu CY, Hsu YH, Wu MT, Pan PC, Ho CK, Su L, Xu X, Li Y, Christiani DC, Kaohsiung Leukemia Research Group: Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study. BMC Cancer; 2009 Jan 13;9:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study.
  • This study investigated whether consumed cured/smoked meat and fish, the major dietary resource for exposure to nitrites and nitrosamines, is associated with childhood acute leukemia.
  • 145 acute leukemia cases and 370 age- and sex-matched controls were recruited between 1997 and 2005.
  • RESULTS: Consumption of cured/smoked meat and fish more than once a week was associated with an increased risk of acute leukemia (OR = 1.74; 95% CI: 1.15-2.64).
  • No statistically significant association was observed between leukemia risk and the consumption of pickled vegetables, fruits, and tea.
  • CONCLUSION: Dietary exposure to cured/smoked meat and fish may be associated with leukemia risk through their contents of nitrites and nitrosamines among children and adolescents, and intake of vegetables and soy-bean curd may be protective.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:79-82 [12505288.001]
  • [Cites] Comp Biochem Physiol A Comp Physiol. 1989;93(1):285-90 [2568231.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5111-7 [2548712.001]
  • [Cites] J Natl Cancer Inst. 1991 Apr 17;83(8):541-6 [1672382.001]
  • [Cites] Cancer Causes Control. 1991 Nov;2(6):427-42 [1764568.001]
  • [Cites] Eur J Cancer Prev. 1993 Mar;2(2):139-46 [8461864.001]
  • [Cites] Nature. 1993 May 27;363(6427):358-60 [8497319.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):141-8 [8167261.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):195-202 [8167267.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):790S-797S [7533831.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):901-6 [8922298.001]
  • [Cites] Blood. 1997 Jan 1;89(1):281-5 [8978302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Radiat Environ Biophys. 1998 Feb;36(4):217-28 [9523337.001]
  • [Cites] Cancer Causes Control. 1998 Dec;9(6):553-7 [10189040.001]
  • [Cites] Am J Clin Nutr. 1999 Sep;70(3 Suppl):464S-474S [10479219.001]
  • [Cites] Am J Epidemiol. 2004 Dec 1;160(11):1098-107 [15561989.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):163-5 [15540221.001]
  • [Cites] Free Radic Biol Med. 2005 Jul 15;39(2):257-65 [15964517.001]
  • [Cites] Nutr Cancer. 2006;54(1):111-42 [16800779.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Nutr Cancer. 2006;56(2):225-31 [17474869.001]
  • [Cites] J Nutr. 2008 Apr;138(4):775-81 [18356334.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):984-90 [18339682.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):176-84 [18614739.001]
  • [Cites] Am J Epidemiol. 1999 Nov 1;150(9):930-8 [10547138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3 [10781030.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):665-8 [12869409.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):667-71 [15158086.001]
  • [Cites] Free Radic Biol Med. 2004 Jun 15;36(12):1505-16 [15182853.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):559-70 [15280635.001]
  • [Cites] Ann N Y Acad Sci. 1980;355:267-79 [6940481.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1985;2(1):7-10 [3903369.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):603-9 [10797279.001]
  • [Cites] J Nutr. 2000 Aug;130(8):1887-93 [10917898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1051-8 [11045787.001]
  • [Cites] Free Radic Res. 2001 Sep;35(3):215-31 [11697121.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):777-81 [12163333.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):815-21 [12223424.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Mar;24(3):403-11 [3383943.001]
  • (PMID = 19144145.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES00002; United States / NIEHS NIH HHS / ES / ES09723
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653540
  • [Investigator] Chang TT; Lin SF; Chiou SS; Jang RC; Hsiao HH; Liu TC; Lin PC; Hsiao CC; Sheen JM; Kuo CY; Wang MC; Huang CH; Huang CB; Wong YC; Wu HB; Lin SJ; Sun YM; Hsieh KS; Chang YH
  •  go-up   go-down


78. Patterson TF, Mackool BT, Gilman MD, Piris A: Case records of the Massachusetts General Hospital. Case 22-2009. A 59-year-old man with skin and pulmonary lesions after chemotherapy for leukemia [corrected]. N Engl J Med; 2009 Jul 16;361(3):287-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case records of the Massachusetts General Hospital. Case 22-2009. A 59-year-old man with skin and pulmonary lesions after chemotherapy for leukemia [corrected].
  • [MeSH-major] Antineoplastic Agents / adverse effects. Dermatomycoses / pathology. Fusarium / isolation & purification. Leukemia, Myeloid, Acute / drug therapy. Lung Diseases, Fungal / pathology. Opportunistic Infections / pathology. Skin / pathology
  • [MeSH-minor] Antifungal Agents / adverse effects. Antifungal Agents / therapeutic use. Biopsy. Bone Marrow Examination. Bone Marrow Transplantation. Diagnosis, Differential. Drug Antagonism. Fatal Outcome. Humans. Immunocompromised Host. Lung / pathology. Lung / radiography. Male. Middle Aged. Myelodysplastic Syndromes / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] N Engl J Med. 2009 Oct 1;361(14):1416
  • (PMID = 19605834.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


79. Chaudhary P, Shah C: Update on MDS therapy: from famine to feast. Cardiovasc Hematol Agents Med Chem; 2010 Oct 1;8(4):187-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelodysplastic syndromes (MDS) are acquired hematopoietic stem cell disorders characterized by ineffective hematopoiesis, cellular dysfunction and increased risks of transformation into acute myeloid leukemia.
  • The natural history of the disease remains variable and depend upon multiple prognostic factors at the time of initial diagnosis.
  • There are several FDA approved therapies available for this disorder that makes this review particularly timely and relevant.

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712577.001).
  • [ISSN] 1875-6182
  • [Journal-full-title] Cardiovascular & hematological agents in medicinal chemistry
  • [ISO-abbreviation] Cardiovasc Hematol Agents Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


80. Wang XD, Chen J: [Aml1 gene abnormality in pediatric acute leukemia-review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug;17(4):1078-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aml1 gene abnormality in pediatric acute leukemia-review].
  • Acute leukemia, the most common cancer in childhood, affects children's health severely, whereas the pathogeny and mechanism have not been elucidated clearly yet.
  • As many studies showed, it has been found that transformation of cytogenetics plays a crucial role in leukemia development, and is frequently involved in the transforming action of aml1 gene, one of which is essential for regulation of normal hematogenesis.
  • Moreover, in children acute leukemia, more than one third children with acute leukemia can be detected with dysfunction of the aml1 gene.
  • Our findings highlight the translocation of aml1 gene in children acute leukemia, indicating its mechanism, especailly provide a new target for clinical diagnosis and therapy.
  • In this review, the structure and function of aml1 gene, the abnormality of aml1 gene in acute lymphocytic leukemia, abnormality of aml1 gene in acute myeloid leukemia and so on were summarized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698265.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
  •  go-up   go-down


81. Patnaik MM, Tefferi A, Pardanani A: Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets; 2007 Aug;7(5):492-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders.
  • Kit a type III receptor tyrosine kinase, along with its ligand the stem cell factor, play a critical role in normal cell growth, differentiation, development and survival.
  • Ligand independent activation of kit (dysregulated kit function) has been found to be an important component of oncogenesis in a large number of neoplastic disorders such as systemic mastocytosis, gastro intestinal stromal tumors, germ cell tumors, acute myelogenous leukemia with the disruption of the core binding factor, amongst others.
  • Non-tyrosine kinase inhibitors like rapamycin, 17-AAG and IMD- 0354 have been added to the therapeutic armamentarium, with the hope that combination therapy might have a synergistic effect, or prevent/delay the development of drug resistance.
  • [MeSH-major] Mastocytosis / diagnosis. Mastocytosis / metabolism. Neoplasms / diagnosis. Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Animals. Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / enzymology. Gastrointestinal Stromal Tumors / metabolism. Humans

  • Genetic Alliance. consumer health - Mast cell disease.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17691909.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 175
  •  go-up   go-down


82. Paczesny S, Levine JE, Braun TM, Ferrara JL: Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant; 2009 Jan;15(1 Suppl):33-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma biomarkers in graft-versus-host disease: a new era?
  • Acute graft versus host disease (GVHD) remains a major complication of allogeneic hematopoietic cell transplantation (HCT).
  • The diagnosis of acute GVHD is based on strictly clinical criteria and its severity also determined by these criteria.
  • Currently, there is no validated diagnostic blood test for acute GVHD.
  • If successful, these studies could establish a novel biomarker panel that will contribute important information including long term survival, and that may eventually facilitate therapeutic decisions for allogeneic HCT patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2000 Jun;109(3):652-7 [10886219.001]
  • [Cites] Blood. 2009 Jan 8;113(2):273-8 [18832652.001]
  • [Cites] J Allergy Clin Immunol. 2000 Jul;106(1 Pt 2):S45-50 [10887333.001]
  • [Cites] Bone Marrow Transplant. 2001 Jul;28(2):197-200 [11509938.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1150-6 [12764383.001]
  • [Cites] Transplantation. 2003 Jul 27;76(2):423-6 [12883204.001]
  • [Cites] Exp Hematol. 2003 Nov;31(11):1044-50 [14585368.001]
  • [Cites] Blood. 2004 Jul 15;104(2):340-9 [15054046.001]
  • [Cites] Blood. 1990 Feb 15;75(4):1011-6 [2405918.001]
  • [Cites] Transplantation. 1990 Sep;50(3):518-21 [2402801.001]
  • [Cites] N Engl J Med. 1991 Mar 7;324(10):667-74 [1994250.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1821-8 [2015405.001]
  • [Cites] Blood. 1993 May 1;81(9):2252-6 [8481507.001]
  • [Cites] Bone Marrow Transplant. 1994 Jun;13(6):745-51 [7920309.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Bone Marrow Transplant. 1996 Feb;17(2):185-90 [8640164.001]
  • [Cites] Cytokines Mol Ther. 1996 Dec;2(4):243-50 [9384711.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(1):29-32 [9486491.001]
  • [Cites] Bone Marrow Transplant. 1998 Apr;21(8):769-73 [9603399.001]
  • [Cites] Transplantation. 1998 Oct 15;66(7):863-71 [9798695.001]
  • [Cites] Mol Cell Proteomics. 2005 May;4(5):618-25 [15703445.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4407-11 [16141347.001]
  • [Cites] Transpl Immunol. 2006 Jan;15(3):223-7 [16431290.001]
  • [Cites] Nat Biotechnol. 2006 Mar;24(3):333-8 [16525410.001]
  • [Cites] Exp Hematol. 2006 Jun;34(6):796-801 [16728285.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):64-71 [17030953.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5511-9 [17339419.001]
  • [Cites] J Proteome Res. 2007 Sep;6(9):3558-65 [17696519.001]
  • [Cites] Blood. 2007 Dec 1;110(12):3827-32 [17766680.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4535-42 [17702900.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4403-12 [18256320.001]
  • [Cites] J Allergy Clin Immunol. 2000 Jul;106(1 Pt 2):S40-4 [10887332.001]
  • (PMID = 19147075.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA039542-20; United States / NCI NIH HHS / CA / P01 CA039542; United States / NCI NIH HHS / CA / P01 CA039542-20
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 32
  • [Other-IDs] NLM/ NIHMS89618; NLM/ PMC2644447
  •  go-up   go-down


83. Sirulnik LA, Stone RM: Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease. Clin Adv Hematol Oncol; 2005 May;3(5):391-7, 429
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease.
  • Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that comprises about 10% of cases.
  • Current treatment strategies with ATRA and anthracycline-based chemotherapy has dramatically transformed APL into the most curable of all acute leukemias.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167012.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 69
  •  go-up   go-down


84. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH, Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood; 2006 Jul 15;108(2):465-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
  • Outcome of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) disease at diagnosis is unclear.
  • We treated 1508 de novo ALL patients with 2-phase induction and then high-dose methotrexate with l-asparaginase.
  • Patients up to 50 years old in first remission (CR1) with a matched related donor (MRD) underwent an allogeneic stem cell transplantation (SCT); the remainder in CR1 were randomized to an autologous SCT or intensive consolidation followed by maintenance chemotherapy.
  • Seventy-seven of 1508 (5%) patients a median age of 29 years had CNS leukemia at presentation; 13 of the 77 (17%) had Ph-positive ALL.
  • Seven of 27 treated with consolidation/maintenance remain in CR1 56 to 137 months after diagnosis.
  • Overall survival at 5 years was 29% in those with CNS involvement at diagnosis versus 38% (P = .03) for those without.
  • CNS leukemia in adult ALL is uncommon at diagnosis.
  • Adult Ph-negative ALL patients, however, can attain long-term disease-free survival using SCT as well as conventional chemotherapy.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Br J Haematol. 1994 Sep;88(1):94-100 [7803263.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):70-82 [9045306.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2017-25 [10811665.001]
  • [Cites] Leukemia. 2001 Feb;15(2):208-16 [11236936.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):40-6 [14695849.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Med Pediatr Oncol. 1986;14(3):191-4 [3528788.001]
  • [Cites] Blood. 1987 Apr;69(4):1015-20 [3548841.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Blood. 1989 Jan;73(1):57-63 [2642717.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:175-7 [1578926.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:49-51 [1434832.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):314-9 [8321259.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1990-2001 [8410124.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2091-7 [7662956.001]
  • (PMID = 16556888.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1895498
  •  go-up   go-down


85. Dimou J, Jithoo R, Tsui A, Morokoff AP: Spinal cord compression as the initial presentation of acute biphenotypic leukaemia. J Clin Neurosci; 2009 Dec;16(12):1696-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression as the initial presentation of acute biphenotypic leukaemia.
  • Acute biphenotypic leukaemia (BAL) is an uncommon haematological malignancy with features of myeloid and lymphoid origin and poor overall prognosis.
  • Histopathology confirmed the diagnosis of acute biphenotypic (B/myeloid) leukaemia.
  • He succumbed to the disease three months post-diagnosis after failing induction chemotherapy.
  • While central nervous system involvement with acute leukaemia is well recognised, this is the first reported patient with spinal cord compression secondary to this leukaemia subtype.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / etiology. Spinal Cord Compression / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815414.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, CD79; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


86. Bloomfield CD, Mrózek K, Caligiuri MA: Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions. Clin Cancer Res; 2006 Jun 1;12(11 Pt 2):3564s-71s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions.
  • The Cancer and Leukemia Group B (CALGB) Leukemia Correlative Science Committee (LCSC) has a remarkable history of outstanding productivity and has been at the cutting edge of correlative science for adult leukemia for almost 25 years.
  • Its work, initially focused on the use of immunophenotyping for diagnosis and prognosis of acute lymphoblastic leukemia and acute myeloid leukemia, has, for the last 15 years, focused on the clinical use of cytogenetic and molecular genetic markers in acute myeloid leukemia and acute lymphoblastic leukemia as well as in chronic lymphocytic leukemia.
  • Numerous CALGB LCSC studies have had a major effect on the way we currently diagnose, predict outcome, select appropriate treatment, document complete remission, and monitor residual disease in adults with acute leukemia.
  • In part as a result of the work of the CALGB LCSC, we are increasingly moving toward molecularly targeted therapy in acute and chronic leukemias.
  • In this report, we briefly review those contributions from the CALGB LCSC that have had, or are likely to have in the future, a major effect on how we currently manage leukemia and outline directions of ongoing and future research conducted by the CALGB LCSC.
  • [MeSH-major] Cytogenetics / trends. Leukemia / genetics. Molecular Biology / trends. Societies, Medical / trends

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740786.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


87. Silveira CC, Gorini MI: [Conceptions of the acute myeloid leukemia patient concerning fatigue]. Rev Gaucha Enferm; 2009 Mar;30(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conceptions of the acute myeloid leukemia patient concerning fatigue].
  • [Transliterated title] Concepções do portador de leucemia mielóide aguda frente à fadiga.
  • The present work is a study with the objective of learning the conceptions of the patient bearer of acute myeloid leukemia (AML) concerning to fatigue symptoms and their repercussions in his/her daily life as well as the actions performed in order to minimize the fatigue.
  • Eight (8) adult subjects with diagnosis of AML were interviewed.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653554.001).
  • [ISSN] 0102-6933
  • [Journal-full-title] Revista gaucha de enfermagem
  • [ISO-abbreviation] Rev Gaucha Enferm
  • [Language] POR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


88. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB: Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol; 2007 Mar 1;25(7):813-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
  • PURPOSE: Historically, adolescents with acute lymphoblastic leukemia (ALL) have had inferior outcomes when compared with younger children.
  • Adolescents were more likely to present with T-cell phenotype (P < .001) and less likely to have the TEL-AML1 fusion (P = .05).
  • CONCLUSION: Adolescents were more likely to present at diagnosis with biologically higher risk disease (T-cell phenotype and absence of the TEL-AML1 fusion) and more likely to experience treatment-related complications than younger children.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327603.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 68484
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


89. Tan Y, Shi L, Tong W, Wang C: Multi-class cancer classification by total principal component regression (TPCR) using microarray gene expression data. Nucleic Acids Res; 2005;33(1):56-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA microarray technology provides a promising approach to the diagnosis and prognosis of tumors on a genome-wide scale by monitoring the expression levels of thousands of genes simultaneously.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):1104-11 [15531609.001]
  • [Cites] Bioinformatics. 2002 Aug;18(8):1054-63 [12176828.001]
  • [Cites] Bioinformatics. 2002 Sep;18(9):1216-26 [12217913.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):261-6 [12219088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):262-7 [10618406.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):236-44 [10700175.001]
  • [Cites] J Chem Inf Comput Sci. 2000 Mar-Apr;40(2):367-79 [10761142.001]
  • [Cites] Cell. 2000 Jul 7;102(1):9-15 [10929708.001]
  • [Cites] FEBS Lett. 2000 Aug 25;480(1):17-24 [10967323.001]
  • [Cites] Bioinformatics. 2000 Oct;16(10):906-14 [11120680.001]
  • [Cites] N Engl J Med. 2001 Feb 22;344(8):539-48 [11207349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Comput Biol. 2000;7(6):819-37 [11382364.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Genomics. 2002 Jan;79(1):104-13 [11827463.001]
  • [Cites] Bioinformatics. 2002 Jan;18(1):39-50 [11836210.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Nov;1(4):363-5 [11901842.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6562-6 [11983868.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:490-5 [12454643.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Bioinformatics. 2003 Mar 22;19(5):571-8 [12651714.001]
  • [Cites] Hum Genet. 2003 May;112(5-6):581-92 [12607117.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1132-9 [12801874.001]
  • [Cites] FEBS Lett. 2003 Sep 11;551(1-3):3-7 [12965195.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1599-604 [14583755.001]
  • [Cites] Bioinformatics. 2003 Nov 1;19(16):2072-8 [14594712.001]
  • [Cites] FEBS Lett. 2004 Mar 12;561(1-3):186-90 [15013775.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1436-46 [14962916.001]
  • [Cites] Comput Biol Chem. 2004 Jul;28(3):235-44 [15261154.001]
  • [Cites] Anticancer Res. 1992 Jul-Aug;12(4):1035-53 [1503399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):33-7 [9915498.001]
  • [Cites] FEBS Lett. 1999 May 21;451(2):142-6 [10371154.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S120-7 [12169539.001]
  • (PMID = 15640445.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000425; United States / NCRR NIH HHS / RR / M01-RR00425
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC546133
  •  go-up   go-down


90. Li Y, Dai Y, Wu SL, Pei P, Cao XH, Pu DF: [The C46359T polymorphism of DNMT3B promoter gene and pathogenesis of acute leukemia]. Zhonghua Nei Ke Za Zhi; 2005 Aug;44(8):588-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The C46359T polymorphism of DNMT3B promoter gene and pathogenesis of acute leukemia].
  • OBJECTIVE: To explore the relationship between the polymorphism of C46359T in DNMT3B promoter and the pathogenesis of acute leukemia (AL).
  • Compared with TT homozygote, CT heterozygote had a 4.669-fold increased risk of acute leukemia (OR = 4.669; 95% confidence interval 1.700-14.747).
  • [MeSH-major] DNA (Cytosine-5-)-Methyltransferase / genetics. Leukemia / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Asian Continental Ancestry Group / genetics. European Continental Ancestry Group / genetics. Female. Gene Frequency. Genotype. Humans. Male. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194411.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


91. Styczynski J: Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol; 2007 Apr;8(2):59-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug resistance in childhood acute myeloid leukemia.
  • AML is considered a stem cell disease.
  • BCRP, PGP and MRP's are preferentially expressed in leukemic stem cells, making this disease drug resistant.
  • Pediatric and adult AML, respectively, are possibly equally drug resistant on initial diagnosis and at relapse.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control


92. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, Ravindranath Y, Dahl G, Weinstein HJ, Children's Oncology Group (COG): A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood; 2006 Jun 15;107(12):4606-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481.
  • A unique transient leukemia (TL) has been described in newborns with Down syndrome (DS; or trisomy 21 mosaics).
  • This leukemia has a high incidence of spontaneous remission; however, early death and subsequent development of acute megakaryoblastic leukemia (AMKL) have been reported.
  • We prospectively evaluated 48 infants with DS and TL to determine the natural history and biologic characteristics of this disease, identify the clinical characteristics associated with early death or subsequent leukemia, and assess the incidence of subsequent leukemia.
  • Blast cells associated with TL in DS infants exhibited FAB M(7) morphology and phenotype.
  • Most infants (74%) had trisomy 21 (or mosaicism) as the only cytogenetic abnormality in the blast cells.
  • Early death occurred in 17% of infants and was significantly correlated with higher white blood cell count at diagnosis (P < .001), increased bilirubin and liver enzymes (P < .005), and a failure to normalize the blood count (P = .001).
  • Recurrence of leukemia occurred in 19% of infants at a mean of 20 months.
  • Development of leukemia was significantly correlated with karyotypic abnormalities in addition to trisomy 21 (P = .037).
  • Ongoing collaborative clinical studies are needed to determine the optimal role of chemotherapy for infants at risk for increased mortality or disease recurrence and to further the knowledge of the unique biologic features of this TL.
  • [MeSH-major] Chromosomes, Human, Pair 21. Down Syndrome. Leukemia, Megakaryoblastic, Acute. Mosaicism. Trisomy
  • [MeSH-minor] Bilirubin / blood. Blast Crisis / blood. Blast Crisis / mortality. Blast Crisis / pathology. Enzymes / blood. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Leukocyte Count. Male. Prospective Studies. Recurrence

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2006 Dec 1;108(12):3952-3; author reply 3953 [17114573.001]
  • (PMID = 16469874.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzymes; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


93. Muccio CF, Catapano G, Di Blasi A, Esposito G, Cerase A: Giant cystic intraventricular cerebral cavernous malformation: MRI with pathologic correlation. A case report. Neuroradiol J; 2008 Oct 01;21(4):547-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the MRI findings and histological features of an uncommon case of a single giant (maximum diameter: >6 cm) cystic CCM of the left lateral ventricle occurring in a 26-year-old man who had undergone 30 Gy cranial irradiation for acute leukemia at the age of six years.
  • Large cystic CCMs must be included in the neuroradiological differential diagnosis of intraventricular hemorrhagic cystic lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24256962.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Ramzi M, Nourani H, Zakerinia M, Dehghani M, Vojdani R, Haghshenas M: Results of hematopoietic stem cell transplant in Shiraz: 15 years experience in southern Iran. Exp Clin Transplant; 2010 Mar;8(1):61-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of hematopoietic stem cell transplant in Shiraz: 15 years experience in southern Iran.
  • OBJECTIVES: Over the past 2 decades, hematopoietic stem cell transplant has evolved from an experimental procedure to the standard of care, and it is integrated into the management of many diseases.
  • Hematopoietic stem cell transplant was established at Shiraz University of Medical Sciences in 1993.
  • Here, we describe 15 years experience with stem cell transplant at our center in southern Iran.
  • We provide information on indication, donor type, conditioning chemotherapy regimen, outcome, survival, and long-term follow-up in our stem cell activity.
  • PATIENTS AND METHODS: From May 1993 to October 2008, 423 patients underwent allogeneic (n=311) and autologous (n=112) stem cell transplants at our center.
  • For allogeneic stem cell transplant, the conditioning chemotherapy regimen comprised busulfan, cyclophosphamide, and antithymocyte globulin for thalassemic patients; busulfan and cyclophosphamide for leukemia patients; and cyclophosphamide and antithymocyte globulin for patients with aplastic anemia.
  • Of 155 patients with a diagnosis of thalassemia major, 112 are alive (72%) with full engraftment after a median follow-up of about 8.1 years (range, 12-184 months).
  • During this time, 127 leukemia patients including acute myelogenous leukemia (n=68), acute lymphoblastic leukemia (n=30) and chronic myelogenous leukemia (n=29), received allogeneic stem cell transplant.
  • In this group, long-term, disease-free survival (cure rate) was 67%, 60%, and 62%.
  • CONCLUSIONS: These data reflect the important role of hematopoietic stem cell transplant in improving survival for a variety of hematopoietic system disorders at our center in Southern Iran.
  • In patients with B-thalassemia major hematopoietic stem cell transplant seems to be the treatment of choice, because it leads to a cure in all classes (Lucarelli risk group, I-III).
  • Based on high success rates in patients with class II and III thalassemia with the addition of the antithymocyte globulin to conditioning regimen of stem cell transplant, we also recommend using this new method of conditioning in transplant of thalassemia patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. beta-Thalassemia / surgery

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20199373.001).
  • [ISSN] 2146-8427
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


95. Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A: Treatment options for essential thrombocythemia and polycythemia vera. Expert Rev Hematol; 2009 Feb;2(1):41-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major causes of morbidity and mortality are represented by arterial and venous thrombosis, as well as by evolution to myelofibrosis or transformation to acute leukemia.
  • However, results of clinical trials with interferon, and the expected effects of novel drugs selectively targeting the abnormal pathways that are involved in the clonal myeloproliferation, are pushing therapeutic goals from disease control only to cure.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082994.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


96. Kokandakar HR, Tembhare PR, Mamoon A, Mulay VM, Bhople KS: Acute basophilic leukaemia: a case report. Indian J Pathol Microbiol; 2007 Apr;50(2):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute basophilic leukaemia: a case report.
  • Acute basophilic leukaemia is an uncommon form of acute leukaemia, rarely occurring as de novo disease.
  • Due to rarity of the disease, consistent diagnostic criteria for the identification of this entity still remain the topic of discussion.
  • We present a case of acute basophilic leukaemia with (11q23)-MLL gene rearrangement, in an 18-year-old male with review of literature and discussion of diagnostic criteria.
  • [MeSH-major] Leukemia, Basophilic, Acute / diagnosis
  • [MeSH-minor] Adolescent. Coloring Agents. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Staining and Labeling. Tolonium Chloride

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883105.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 15XUH0X66N / Tolonium Chloride; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 11
  •  go-up   go-down


97. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, Marsh SG: Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol; 2007 Sep 20;25(27):4262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.
  • PURPOSE: Hematopoietic stem cell transplantation (HSCT) is an important option in the management of acute leukemia, but the risk of disease relapse and death remains appreciable.
  • Recent studies have suggested that nucleotide-binding oligomerization domain 2 (NOD2)/caspase recruitment domain 15 (CARD15) gene single nucleotide polymorphisms (SNPs), implicated in innate immunity and Crohn's disease, may also affect immune function post-HSCT.
  • PATIENTS AND METHODS: NOD2/CARD15 genotypes were analyzed in 196 patients diagnosed with acute leukemia and their unrelated donors.
  • The pairs are part of a previously well-characterized cohort with a median follow-up of 2.2 years (range, 0.42 to 6.61 years).
  • T-cell depletion was used in 83% of pairs.
  • RESULTS: NOD2/CARD15 SNPs were associated with a reduction in overall survival (44% v 22%; log-rank P = .0087) due to an increase in disease relapse (32% v 54%; Gray's test P = .001) as compared with wild-type pairs.
  • The incidence of acute graft-versus-host disease was low and there was no significant difference due to the presence of SNPs.
  • CONCLUSION: These data indicate an unrecognized role for the NOD2/CARD15 gene in unrelated donor HSCT for acute leukemia.
  • The increased risk of disease relapse suggests that the wild-type gene product may contribute to a graft-versus-leukemia effect.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Nod2 Signaling Adaptor Protein / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. HLA Antigens / metabolism. Hematopoietic Stem Cell Transplantation. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jan 10;26(2):338-9; author reply 339 [18182678.001]
  • (PMID = 17724347.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0200231
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Immunosuppressive Agents; 0 / NOD2 protein, human; 0 / Nod2 Signaling Adaptor Protein
  •  go-up   go-down


98. Park TS, Lee ST, Song J, Lee KA, Lee JH, Kim J, Lee HJ, Han JH, Kim JK, Cho SR, Choi JR: Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits. Cancer Genet Cytogenet; 2009 Mar;189(2):87-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits.
  • We report on a 20-year-old man with acute myeloid leukemia (AML) showing a distinct novel CBFB/MYH11 variant fusion transcript.
  • Initial results of bone marrow, chromosome, and flow cytometric analyses were not in accordance with the diagnosis of acute myelomonocytic leukemia with eosinophilia (AML-M4Eo) or AML with a CBFB/MYH11 rearrangement.
  • Not only does this case show a partial insertion of exon 6 of the CBFB (ENSG00000067955) gene, but it also involves novel breakpoints within both exon 6 of the CBFB gene and exon 28 (previously exon 7) of the MYH11 (ENSG00000133392) gene, which is regarded as a previously non-reported, new type (K-type) of CBFB/MYH11 fusion transcript.
  • [MeSH-major] Core Binding Factor beta Subunit / genetics. Leukemia, Myeloid, Acute / genetics. Mutagenesis, Insertional. Myosin Heavy Chains / genetics. Reagent Kits, Diagnostic. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215788.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBFB protein, human; 0 / Core Binding Factor beta Subunit; 0 / MYH11 protein, human; 0 / Reagent Kits, Diagnostic; 0 / Recombinant Fusion Proteins; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


99. Yao L, Chen Z, Cen J, Liang J, Feng Y, He J, Qi X, Shen H: The pattern of clonal immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Chinese adult acute lymphoblastic leukemia patients. Leuk Res; 2008 Nov;32(11):1735-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of clonal immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Chinese adult acute lymphoblastic leukemia patients.
  • We have studied forty Chinese adult ALL patients at newly diagnosis, using standard primers and protocols of BIOMED-2 multiplex PCR, to determine the feasibility of Ig and TCR gene rearrangements as diagnostic and patient-specific MRD-RQ-PCR targets for molecular monitoring.
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor / genetics. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Genes, Immunoglobulin / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18456325.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


100. Gangat N, Wolanskyj AP, Tefferi A: Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol; 2006 Oct;77(4):327-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 460 consecutive patients with essential thrombocythemia (ET) seen at our institution, 19 cases (4%) of abdominal vein thrombosis (AVT) were documented either at (n = 9) or after (n = 10) diagnosis.
  • Accordingly, clinical comparisons were performed among three groups of female patients: those with AVT (group A; n = 17), a control group without AVT but closely matched to group A in terms of age and year of diagnosis (group B; n = 34), and all female patients without AVT (group C; n = 288).
  • Unexpectedly, however, compared with group B, group A displayed both a higher conversion rate into myelofibrosis/acute leukemia (P = 0.0008) and a shorter median survival (116 vs. 156 months; P = 0.0012).
  • Multivariable analysis including all female patients with ET identified AVT, along with advanced age, leukocytosis, and tobacco use, as an independent risk factor for inferior survival.
  • Groups A, B, and C did not differ in either JAK2(V617F) mutational frequency or incidence of non-abdominal thrombosis.
  • We conclude that AVT in ET is a marker of aggressive disease biology.






Advertisement